Appendix K — Glossary

Every term this book defines, in one place. The chapter that owns each term is named in parentheses; that is where the concept is developed in full. Terms are defined once and used freely thereafter, which is why a definition here may be shorter than the treatment in the chapter.

931 terms.

"I don't know" — this particular clinician has not looked into it. Says nothing about the state

"It doesn't work" — the evidence exists and is negative. A strictly stronger claim than the

"We don't know" — the evidence is absent. Nobody has run the study.

"What would change your mind?" — the repair move for a category dismissal, and the same question

2-aminoisobutyric acid (Aib) — A non-proteinogenic amino acid: alanine bearing a second methyl

500-dalton rule — A rule of thumb from the dermatology literature holding that molecules above

503A — traditional pharmacy compounding in the United States, performed on patient-specific prescriptions and exempt from certain requirements including premarket approval (Ch. 38).

503A compounding pharmacy — Prepares medications for individually identified patients under valid

503A pharmacy — a compounding pharmacy preparing medications for individually identified patients pursuant to a prescription. (Ch.6)

503B outsourcing facility — a compounder permitted to produce larger batches without patient-specific prescriptions, subject to more stringent manufacturing requirements than a 503A. (Ch.6)

A

A1C (glycated hemoglobin) — the fraction of hemoglobin with glucose attached, reflecting average blood glucose over roughly three months; the standard endpoint in diabetes trials, and a surrogate for the complications of diabetes. (Ch.8)

Abaloparatide — a synthetic analog of parathyroid hormone-related protein, PTHrP(1–34), acting at

Absolute risk reduction — the difference in risk between groups, in percentage points; the figure that determines what an individual can expect. (Ch.5)

Absorption enhancer — an excipient co-formulated with a drug to increase its absorption across an epithelial barrier, making oral delivery of a molecule that would otherwise be destroyed or excluded partially possible.

Accelerated approval — A conditional regulatory approval granted on the basis of a surrogate

Accelerated blood clearance — The phenomenon in which a repeat dose of a PEGylated agent is

Acetyl hexapeptide-8 — A six-residue cosmetic peptide of roughly 890 daltons derived from a

Achondroplasia — the most common form of disproportionate short stature, caused by a

Acromegaly — Chronic growth hormone excess in adulthood, almost always caused by a benign pituitary adenoma. Produces soft-tissue and skeletal overgrowth, arthropathy, cardiomyopathy, insulin resistance and diabetes, sleep apnea, increased colonic polyps, and reduced life expectancy that improves with biochemical control. The natural experiment for chronic elevation of the growth axis. (Ch.14)

Actin-binding domain — The region of thymosin β4 that interacts with actin; the structural basis

activating reagent — A compound that converts an amino acid's carboxyl group into a much more

Active comparator — a control arm receiving a treatment already known to work, rather than placebo. The hardest test and the most useful result, which is why Chapter 28's sacubitril/valsartan trial changed practice.

Active pharmaceutical ingredient (API) — The drug substance itself, before formulation. Its provenance determines whether anything downstream of it can be trusted. (Ch.12)

Activin A — A TGF-β superfamily member signaling through ActRIIB, involved in reproductive

Activin receptor type IIB (ActRIIB) — The type II receptor through which myostatin signals, shared

Acylation — See lipidation. — Ch 33 §33.4

Addiction (opioid use disorder) — a clinical diagnosis defined by a behavioral pattern: compulsive

Adjuvant [NEW] — the component of a vaccine that supplies the innate danger signal required to

Adult growth hormone deficiency — Growth hormone deficiency arising in or persisting into adult life, usually from pituitary disease, pituitary surgery, cranial radiation, or traumatic brain injury. (Ch.14)

Adverse event report — A submitted account of a suspected harm associated with a medicine.

Afamelanotide (melanotan I) — A linear analog of α-MSH with high MC1R activity, approved to

Affinity — how tightly a ligand binds its receptor. High affinity means binding occurs at lower concentrations and persists longer. (Ch.2)

Aggregation — the clumping together of peptide molecules in solution, which reduces active drug and substantially increases immunogenic risk. (Ch.4)

Agonist — a ligand that binds a receptor and activates it. (Ch.2)

AgRP (agouti-related peptide) — an endogenous MC4R blocker released by hypothalamic neurons that leptin inhibits; blocking the receptor increases hunger. (Ch.13)

Aib (2-aminoisobutyric acid) — a non-proteinogenic amino acid used to block enzymatic cleavage; the position-8 modification in semaglutide. (Ch.4)

Albumin binding — attachment of a drug to albumin, the most abundant blood protein, dramatically extending half-life by defeating renal filtration and shielding the drug from proteases. (Ch.4)

Albumin binding (as a design strategy) — Reversible, non-covalent association of a lipidated

Albuminuria — protein in the urine; a marker of kidney damage. (Ch.10)

Allergen immunotherapy [NEW] — repeated controlled allergen exposure intended to induce

Allometric scaling — the non-linear conversion of dose between species based on body mass and metabolic rate; the reason a milligram-per-kilogram figure in a rat does not correspond to the same figure in a human. (Ch.17)

Alpha cell — the pancreatic islet cell that produces and secretes glucagon. (Ch.7)

Alpha helix — a coiled secondary structure with approximately 3.6 residues per turn and side chains projecting outward; the most common shape in peptide hormones. (Ch.1)

Alpha-melanocyte-stimulating hormone (α-MSH) — The endogenous melanocortin peptide, cleaved from

AlphaFold — DeepMind's computational method for predicting protein structure from amino acid

AMDUCA (Animal Medicinal Drug Use Clarification Act) — The U.S. statute establishing the

Amino acid — the building block of peptides and proteins: a central (alpha) carbon bearing an amino group, a carboxyl group, a hydrogen, and a variable R group. Twenty are used in human biology. (Ch.1)

Amino acid analysis (AAA) — complete hydrolysis of a peptide followed by separation and

Amphipathic — Having spatially segregated hydrophobic and hydrophilic faces. In an α-helical AMP

Amplification — the multiplication of signal at each step of a cascade, allowing trace ligand concentrations to produce large cellular responses. (Ch.2)

Amylin — a 37-amino-acid peptide co-secreted with insulin from pancreatic beta cells; slows gastric emptying, suppresses postprandial glucagon, and promotes satiety. (Ch.13)

Amylin analog — a compound mimicking amylin, a peptide co-secreted with insulin that slows gastric emptying and promotes satiety. (Ch.9)

Anabolic agent (bone) — a drug that stimulates new bone formation rather than merely slowing the

Analgesia — reduction of pain. Where the measurement is a reflex or withdrawal threshold rather

Analog — a molecule deliberately modified from a natural one to change its properties while preserving its activity. Semaglutide is a GLP-1 analog. (Ch.1)

Anchor residues [NEW] — the side chains of a peptide that drop into pockets in the HLA groove

Androgen deprivation therapy (ADT) — Treatment that reduces serum testosterone to castrate levels,

Anergy [NEW] — functional unresponsiveness in a lymphocyte that encountered its antigen without

Angioedema — swelling of the deeper layers of the skin and mucosa, potentially involving the

Angiogenesis — the growth of new blood vessels; central to healing in poorly vascularized tissue such as tendon, and the core of BPC-157's proposed unifying mechanism. (Ch.17)

Anorexigenic — appetite-suppressing. (Ch.13)

ANP (atrial natriuretic peptide) — a 28-amino-acid peptide stored preformed in granules in atrial

Antagonist — a ligand that binds a receptor without activating it, blocking access for the natural ligand. (Ch.2)

Anti-drug antibody — an antibody raised against a therapeutic peptide or protein, which may reduce efficacy, neutralize the drug, or cross-react with the patient's own endogenous molecule. (Ch.4)

Anti-drug antibody (ADA) — An antibody raised against an administered therapeutic. May neutralize

Anti-PEG antibody — An antibody recognizing polyethylene glycol. Both drug-induced and

Antiandrogen — A drug that blocks the androgen receptor, used alongside a GnRH agonist during the

Antidiuretic hormone (ADH) — Alternative name for vasopressin, naming its renal water-retention

Antigen [NEW] — anything the adaptive immune system can recognize; usually a whole protein

Antigen presentation [NEW] — the display of peptide fragments on MHC/HLA molecules at a cell

Antimicrobial peptide (AMP) — A short peptide, typically 12–50 residues, produced as part of

Antimicrobial stewardship — The practice of restricting antibiotic use to preserve

Antiproliferative effect — An effect on tumor growth itself, as distinct from control of the

Antiresorptive — a drug that slows the removal of existing bone by inhibiting osteoclast activity.

Apnea-hypopnea index — the number of apnea and hypopnea events per hour of sleep; the standard objective measure of sleep apnea severity. (Ch.10)

Apoptosis — Programmed cell death; the orderly removal of cells the body no longer wants. IGF-1 inhibits it, which is central both to tissue maintenance and to the cancer question about the growth axis. (Ch.14)

Appendageal route — Penetration of skin via hair follicles and sweat ducts, bypassing the stratum

Approval — a regulator's judgment that, for a specified indication and population, the evidence submitted shows benefits outweigh risks, together with an approved label describing that use. Indication-specific, submission-dependent, jurisdiction-specific, and revisable (Ch. 38).

Approved indication — The specific use a regulator has reviewed and authorized, written into the label together with its population and conditions of use. (Ch.12)

Aprepitant — the first approved NK1 receptor antagonist for CINV; fosaprepitant is its intravenous

Aquaporin-2 — The water channel inserted into the collecting-duct apical membrane in response to V2

Arcuate nucleus — the hypothalamic region containing the principal appetite-regulating neuron populations. (Ch.7)

Area percent purity — purity expressed as the target peak's area divided by the total area of all

Area postrema — a hindbrain region with an incomplete blood-brain barrier, historically identified as the vomiting trigger zone, where circulating peptides can act directly on neurons. (Ch.7)

ARNI (angiotensin receptor–neprilysin inhibitor) — a drug class combining inhibition of

aseptic fill-finish — The final manufacturing operation in which a sterile solution is dispensed

Aseptic processing — Manufacturing that maintains sterility throughout the process rather than sterilizing the sealed finished product. Required where terminal sterilization would destroy the product. (Ch.12)

Aspiration risk — the risk of stomach contents entering the airway, elevated when the reflexes

Associated deaths — In burden-of-disease modeling, all deaths occurring in the presence of the

Atosiban — An oxytocin receptor antagonist used in some countries as a tocolytic to suppress

attachment isomer — One of several molecules with identical composition and identical mass that

Attachment isomer — One of several distinct products formed when a conjugation reaction can occur

Attributable deaths — In burden-of-disease modeling, the excess deaths caused by a factor: those

Attribution of controllability — The judgment an observer makes about how much a person could have

Autocrine — signaling in which a cell responds to a signal it released itself. (Ch.2)

Availability heuristic — judging the likelihood of something by how easily examples come to mind; amplified by search ranking and by testimonial volume. (Ch.6)

Average daily gain (ADG) — Body mass added per day. One of the two primary endpoints of livestock

B

Bacitracin — a cyclic peptide antibiotic, the active agent in most over-the-counter topical

Bacterial endotoxins test (BET) — The assay demonstrating that a product meets a numeric endotoxin

Barrel-stave model — A membrane-disruption mechanism in which peptides insert perpendicular to

Basal insulin — background insulin covering metabolic needs between meals and overnight. (Ch.11)

Base rate — the historical frequency of an outcome in a reference class; here, the low proportion of compounds entering human trials that reach approval, which serves as the prior any pipeline claim must move you off before you grant it anything.

Batch release — The documented decision by a qualified person that a manufactured batch conforms

Beta cell — the pancreatic islet cell that produces and secretes insulin. (Ch.7)

Beta emitter — A radionuclide emitting electrons that travel roughly one to two millimeters in

Beta sheet — an extended, pleated secondary structure formed by backbone strands hydrogen-bonded alongside one another. (Ch.1)

Biased agonism — activation of some downstream signaling pathways from a receptor but not others; a design strategy for separating a drug's benefits from its harms. (Ch.2)

Binding site — the region of a receptor that a ligand occupies. (Ch.2)

Bioavailability — the fraction of an administered dose that reaches the general circulation intact. Intravenous administration is 100% by definition. (Ch.4)

Bioequivalence — the demonstration that a follow-on product delivers the same amount of active drug to the bloodstream on the same time course as the reference product; the evidentiary basis of a generic application (Ch. 38).

Biological product — in United States law, a category that includes alpha-amino-acid polymers with a specific, defined sequence of more than 40 amino acids; licensed through a Biologics License Application (Ch. 38).

Biologics License Application (BLA) — the United States application type for a biological product (Ch. 38).

Biopsy endpoint — a trial endpoint assessed by tissue sampling; invasive, subject to sampling error and reader variability, and generally still a surrogate for the clinical outcomes that matter. (Ch.10)

Biosimilar — a copy of a biologic product demonstrated to be highly similar to its reference product; substantially harder to establish than small-molecule generic equivalence, which is one reason insulin competition was slow. (Ch.11)

Biosimilar competition — Entry of follow-on versions of a complex biologic or peptide after

Blinding — concealing treatment assignment; single-blind conceals it from participants, double-blind from participants and investigators, and open-label conceals it from nobody. (Ch.5)

Blood-brain barrier — the interface between blood and brain tissue formed by tight junctions

BNP (B-type natriuretic peptide) — a 32-amino-acid peptide produced largely by ventricular

Boc (tert-butyloxycarbonyl) — The acid-removable N-terminal protecting group used in Merrifield's

Body surface area normalization — The basis of standard cross-species dose conversion. Yields

Bolus insulin — insulin administered to cover a meal. (Ch.11)

Botulinum toxin — A ~150,000-dalton protein produced by Clostridium botulinum, among the most

Boxed warning — the most prominent form of safety labeling required by the U.S. FDA, applied to warnings judged to require special attention. (Ch.8)

Bradykinin — a vasodilator peptide degraded by both neprilysin and angiotensin-converting enzyme.

Bradykinin-potentiating peptide (BPP) — a class of peptides in Bothrops jararaca venom that

Brand name — The commercial name of a specific product: a molecule, in a formulation, by a route, approved for an indication. One molecule may carry several brand names, and the products are not interchangeable. (Ch.41)

Bremelanotide (PT-141) — A cyclic seven-amino-acid melanocortin receptor agonist with activity at

Budget impact — The total near-term expenditure a therapy imposes on a payer, as distinct from its

C

C-terminal amidation — Conversion of a peptide's C-terminal carboxyl group to an amide. Present in

C-terminus — the end of a peptide chain bearing a free carboxyl group. (Ch.1)

Cagrilintide — a long-acting amylin analog. (Ch.9)

cAMP (cyclic AMP) — the archetypal second messenger, produced by the enzyme adenylyl cyclase. (Ch.2)

capping — Deliberately and permanently blocking chains whose coupling failed, converting deletion

Captopril — an orally available small-molecule ACE inhibitor, approved in the early 1980s,

Carbetocin — A longer-acting oxytocin analog; a heat-stable formulation was developed because

Carcass composition — The distribution of lean tissue, fat, and bone in a slaughtered animal,

Carcinoid syndrome — Flushing, secretory diarrhea, sometimes wheezing, and over time right-sided

Carpet model — A mechanism in which peptides accumulate flat on the surface until the bilayer is

Carrier peptide — A cosmetic peptide proposed to deliver a trace metal cofactor, usually copper,

Case report — a written account of a single patient; valuable for flagging unexpected or harmful events, near-worthless for establishing efficacy, having no control, no blinding, no randomization, and no denominator. (Ch.17)

Cash price — What an uninsured person is quoted. Historically tracks list price closely, because list is the only price they have standing to be charged. (Ch.12)

CASP (Critical Assessment of Structure Prediction) — a biennial blind assessment in which teams

Castrate level — The low serum testosterone threshold that defines successful androgen

Cataplexy — sudden transient loss of muscle tone triggered by strong emotion; the feature that

Category dismissal — rejecting a claim by rejecting the class it belongs to, without engaging

Cathelicidin — A family of host-defense peptides produced as part of innate immunity. LL-37 is the

Cationic — Carrying a net positive charge at physiological pH, typically from lysine and arginine

CD4 T cell (helper T cell) [NEW] — recognizes peptides on class II; does not kill but licenses

CD8 T cell (cytotoxic T lymphocyte) [NEW] — kills cells displaying a recognized peptide on

Center for Veterinary Medicine (CVM) — The division of the U.S. Food and Drug Administration

Central diabetes insipidus (arginine vasopressin deficiency) — Disorder of inadequate vasopressin

Central sensitization — amplification of nociceptive signaling in the central nervous system that

Central tolerance [NEW] — developmental deletion in the thymus of T cells recognizing self

Central versus peripheral action — Whether a drug acts within the brain and spinal cord or in the

certificate of analysis — A document reporting test results for a batch of material. Its

Certificate of analysis (CoA) — A report of analytical tests performed on a sample. A claim about

cGMP (cyclic guanosine monophosphate) — the second messenger produced by guanylyl cyclases,

CGRP (calcitonin gene-related peptide) — a 37-residue peptide produced by alternative splicing of

Chain of custody — documented control of a material from its origin to its point of use. What

Chain of custody (reinforced) — a documented, unbroken record of a substance's handling from

Checkpoint inhibitor [EXT] — a drug blocking inhibitory signals that restrain T cells. Not a

Chelator — A molecular cage, such as DOTA, that binds and holds a metal ion; the component that

Chemotherapy-induced nausea and vomiting (CINV) — the approved indication for NK1 receptor

Chromatogram — the output of a chromatographic separation: detector response plotted against

Chronic therapy — a treatment whose benefit persists only for as long as it is taken; semaglutide for obesity is chronic therapy in this sense, as an antihypertensive or a statin is. (Ch.8)

Circumventricular organ — one of a small number of brain regions where the blood-brain barrier is incomplete, permitting circulating molecules to reach neurons. (Ch.7)

Citation chain — a sequence of sources each citing the next, frequently terminating in a primary paper whose actual content differs from the claim it is invoked to support. (Ch.6)

Citation drift — the progressive loss of qualifying information as a finding is restated across successive citations, characteristically dropping the species first. (Ch.17; introduced Ch.6)

CJC-1295 — A laboratory code applied to a modified GHRH(1-29) fragment, and — in its DAC form — to an albumin-tethered long-acting version of the same. Two pharmacologically different molecules are sold under this one name. (Ch.15)

claim form — A sentence shape that recurs across many different compounds, rated as a form of

Class B GPCR — the G-protein-coupled receptor family including the receptors for GLP-1, GIP,

Class I presentation [NEW] — display of 8–10-residue peptides derived from proteins made inside

Class II presentation [NEW] — display of 13–25-residue peptides derived from externally

Clearance — the volume of blood cleared of a drug per unit time; the underlying process of which half-life is the observable consequence. (Ch.4)

cleavage (from resin) — The final synthesis step releasing the completed chain from the linker,

Clinical attrition — the loss of candidate drugs during human trials. Dominated by lack of

Clinical judgment — a trained decision about a particular patient under uncertainty, with

Clonal mutation [NEW] — a mutation present in every tumor cell; a target the tumor cannot

Closed-loop system — an insulin pump whose delivery is adjusted automatically by an algorithm driven by continuous glucose monitor readings; sometimes called an artificial pancreas, which overstates it, since such systems have no glucagon arm. (Ch.11)

CNP (C-type natriuretic peptide) — a 22-amino-acid peptide produced mainly by endothelial cells

Co-elution — two or more species emerging from a separation column at the same time and being

Co-intervention — a change made at the same time as the treatment under consideration, which may account for an observed improvement. (Ch.6)

Co-transmission — release of more than one signaling molecule from the same neuron, typically a

Coformulation — Delivery of two separate active molecules in a single product, which makes their

Cold chain — the refrigerated storage and transport required to keep a temperature-sensitive product stable from manufacture through to use. (Ch.4)

Colistin (polymyxin E) — A cyclic lipopeptide permeabilizing the Gram-negative outer membrane;

Comparative physiology — The study of physiological variation across species. A productive source

Comparator (reinforced) — what an intervention is being measured against. Every claim of benefit

Compounding — the pharmacy practice of preparing a medication tailored to an individual patient's needs; compounded products are not FDA-approved and are not reviewed for safety or efficacy. (Ch.6)

Compression — Reduction of a claim to a shorter form, losing qualifiers at each step. Chapter 6's central concept; a joke is its terminal case, and the only rung that also loses the claim itself. (Ch.41)

Condensation reaction — a reaction joining two molecules with the release of a small molecule, usually water. Peptide bond formation is one. (Ch.1)

Confidence interval — a range of values consistent with the observed data; more informative than a p-value and less often reported. (Ch.5)

Confirmation bias — the tendency to seek out and credit information supporting what one already believes. (Ch.6)

Conflict of interest — a financial or professional interest that could influence how research is conducted or reported. (Ch.5)

Conformational epitope [NEW] — a surface patch assembled by folding from residues distant in

Confounding by indication — the bias arising when clinicians select which patients receive a treatment, so that the treated group differs systematically from the untreated in ways related to the outcome. (Ch.10)

Conotoxin — one of the short, disulfide-rich peptide toxins produced by marine cone snails

Construct validity — The degree to which an animal model arises from the same underlying

Content (peptide content; assay; potency) — the mass of target peptide actually present in a

Continuity of care — One identifiable clinician holding the longitudinal picture of a patient and

Continuous glucose monitor — a device measuring interstitial glucose continuously and reporting both level and rate of change. (Ch.11)

Control arm — the group in a trial receiving placebo, standard care, or no treatment, against which the treated group is compared. (Ch.5)

Corneocyte — A flattened, dead, keratin-filled cell; the "brick" of the stratum corneum.

Corneometry — Measurement of the electrical capacitance of the stratum corneum, reported as

Cosmeceutical — An informal term for a cosmetic containing biologically active ingredients. No

Cosmetic (regulatory sense) — A product intended to cleanse, beautify, promote attractiveness, or

Cost offset — Expenditure avoided elsewhere in a health system because a treatment prevented an

Costimulation [NEW] — the second signal a T cell requires alongside peptide recognition,

Cosyntropin (tetracosactide) — a synthetic 24-residue fragment of adrenocorticotropic hormone,

Counter-regulation — control of a variable by two opposing signals, each correcting excursions in one direction; insulin and glucagon are the archetype. (Ch.3)

Counter-regulatory hormone — A hormone that opposes insulin's action. Growth hormone opposes insulin peripherally and promotes hepatic glucose output, and therefore raises blood glucose. Sometimes described as diabetogenic. (Ch.14)

Counterfactual — What would have happened otherwise. Randomization is the standard machinery for

counterion — The ion paired with a charged group on a peptide. Trifluoroacetate (TFA) is the

Counterion — an ion of opposite charge accompanying a charged molecule. Synthetic peptides

coupling — The bond-forming step of a synthesis cycle, joining the next protected amino acid to

Cryo-electron microscopy (cryo-EM) — a structural method that reconstructs three-dimensional

Cutometry — Measurement of skin deformation and recovery under applied suction, reported as

Cyclic peptide — A peptide whose chain has been closed into a ring, which raises potency by

Cyclization — Joining a peptide's termini or side chains to form a ring. Removes the free ends

Cyclosporine — a cyclic undecapeptide immunosuppressant isolated from a soil fungus, orally

D

D-amino acid — The mirror-image stereoisomer of a standard amino acid, not used in normal human

DAC (Drug Affinity Complex) — A chemical group designed to bind covalently to circulating albumin, extending a peptide's duration of action from minutes to days. CJC-1295 with DAC carries it; the without-DAC version does not, and the two are pharmacologically different molecules commonly sold under a single name. (Ch.15)

Dalton (Da) — the unit of molecular mass, roughly the mass of a hydrogen atom. Aspirin is ~180 Da; insulin ~5,800 Da; a therapeutic antibody ~148,000 Da. (Ch.1)

Danger signal [NEW] — innate evidence of pathogen presence or tissue damage, detected by

Daptomycin — A calcium-dependent cyclic lipopeptide active against Gram-positive organisms;

Data monitoring committee — an independent group of statisticians and clinicians who review unblinded interim trial results and may recommend stopping for harm or for efficacy. (Ch.10)

date check — The audit check requiring every rating row to carry a date. An undated rating is a

date-stamping — The practice of attaching an explicit assessment date to a rating so it can

db/db mouse — the leptin-receptor-deficient mouse strain; produces leptin in excess and cannot respond to it, demonstrating resistance decades before the molecule was found. (Ch.13)

De novo design — computational design of proteins or peptides with no natural counterpart, using

Defensin — A family of small, disulfide-stabilized, β-sheet antimicrobial peptides. Humans make

Deletion sequence — A peptide missing one residue because a coupling step failed while the chain

deletion sequence — A chain missing one or more internal residues because a coupling failed and

Delta receptor (δ, OPRD1) — an inhibitory GPCR opioid receptor mediating modest analgesia and mood

Dense-core vesicle — the storage vesicle for neuropeptides, located farther from the synaptic

Depot — a formulation designed to release drug slowly over weeks to months after a single administration. (Ch.4)

deprotection — Removal of a protecting group. In each synthesis cycle, the N-terminal cap is

Depsipeptide — A peptide-like molecule in which one or more amide bonds is replaced by an ester

Descending inhibition — modulation of incoming nociceptive signals by circuitry projecting from

Desensitization — rapid uncoupling of a receptor from its signaling machinery following activation, occurring within minutes. (Ch.2)

Desmopressin — V2-selective, longer-acting synthetic vasopressin analog. Approved for central

Desmopressin (DDAVP) — a vasopressin analog engineered for V2 selectivity and extended duration,

DEXA — dual-energy X-ray absorptiometry, a body composition measurement. A surrogate for function, and an unusually treacherous one, because an agent that adds lean mass acts directly on the yardstick.

Diabetic ketoacidosis — the acute metabolic emergency of severe insulin deficiency, in which fat metabolism produces accumulating ketones; fatal within days if untreated. (Ch.11)

Diacid (fatty diacid) — A fatty chain bearing a carboxylate group at both ends. Binds albumin

Diagnostic accuracy — How well a test identifies the presence or absence of a condition, reported as sensitivity, specificity, and predictive values. Never a single number, and never meaningful without a stated population. (Ch.41)

Diagnostic accuracy study — a study design that enrolls patients with a presenting symptom,

Dietary ingredient — the statutory categories a substance must fall into to be lawfully sold as a dietary supplement; regulators have taken the position that certain synthetic peptides do not qualify (Ch. 38).

Dietary supplement — a United States product category created by DSHEA in 1994 with no premarket approval requirement; membership requires that the substance qualify as a dietary ingredient (Ch. 38).

Difelikefalin — a synthetic peptide kappa receptor agonist built from D-amino acids and

Differential diagnosis — the ordered list of possible causes a clinician builds for a

difficult sequence — A stretch of sequence that causes growing chains to aggregate on the resin,

Direct-to-consumer telehealth — A model in which the clinical consultation, the prescription, and the sale of the product are bundled inside one commercial entity. (Ch.12)

Directed evolution — iterated cycles of variation and selection applied to molecules in the

directional bias — A systematic tendency to rate consistently higher or consistently lower than

Disclosure — telling a treating clinician what you are actually taking, including unprescribed

Disclosure norm — A social expectation that certain information be volunteered. This book presents both sides of the medical-disclosure question for public figures and declines to impose a duty. (Ch.41)

Dispensing practice — a clinical practice that supplies the products it recommends from its own

Display technology — any method that maintains a physical link between a candidate molecule and

Distress criterion — The requirement, in certain diagnoses, that the condition cause marked

Disulfide bond — a covalent link between the sulfur atoms of two cysteine residues; biology's staple, holding peptide shapes and separate chains together. (Ch.1)

Dorsal horn — the region of the spinal cord where incoming nociceptive fibers make their first

Dose-response curve — a plot of effect against drug concentration, from which potency (horizontal position) and efficacy (height) can be read. (Ch.2)

Double muscling — The extreme muscularity of certain cattle breeds, notably Belgian Blue and

Downregulation — Reduced receptor number or responsiveness following persistent stimulation. One of two reasons to expect a secretagogue's effect to attenuate over continued use. (Ch.15)

DPP-4 (dipeptidyl peptidase-4) — an enzyme that cleaves two residues from the N-terminus of susceptible peptides; responsible for the ~1–2 minute half-life of native GLP-1. (Ch.4)

drift audit — The five-step dossier procedure in Chapter 37 comparing a reader's own ratings

Drug shortage list — the FDA-maintained list of drugs in shortage; its entries activate a provision permitting compounding of copies of otherwise-unavailable approved drugs. (Ch.6)

DSHEA — the Dietary Supplement Health and Education Act of 1994, which established the United States dietary supplement category and its requirements (Ch. 38).

Dual orexin receptor antagonist (DORA) — an approved class of insomnia medicine (suvorexant,

Dynamic stimulation testing — Provoking hormone release and measuring the response, rather than measuring a static level. Used to diagnose growth hormone deficiency because a snapshot cannot distinguish a healthy trough from true deficiency. (Ch.14)

Dynorphin — a family of endogenous opioid peptides derived from prodynorphin, acting principally at

Dysphoria — an unpleasant, distressed mood state. Characteristically produced by kappa receptor

E

EC50 — the concentration producing half of a drug's maximum effect; the standard measure of potency. (Ch.2)

Ecological fallacy — Inferring something about individuals from patterns observed in aggregates,

Edman degradation — sequential chemical labeling, cleavage, and identification of the N-terminal

Effect size — the magnitude of a difference, as distinct from whether it is statistically significant. (Ch.5)

Efficacy — the maximum effect a drug can produce at any dose; the ceiling of its dose-response curve. (Ch.2)

eGFR (estimated glomerular filtration rate) — the standard estimate of kidney filtering capacity. (Ch.10)

Ejection fraction — the proportion of blood in the left ventricle expelled with each beat. The

Electrospray ionization (ESI) — a soft ionization method in which a solution passed through a fine

Endocrine — signaling via the bloodstream to distant tissues. (Ch.2)

Endocrine gland — an organ that releases hormones into the bloodstream to act on distant tissues. (Ch.3)

Endogenous — produced within the body. The opposite is exogenous — administered from outside. (Ch.1)

Endogenous ligand — the molecule the body itself produces to activate a given receptor; the

Endogenous opioid peptide — any peptide produced by the body that acts at opioid receptors,

Endotoxin — Lipopolysaccharide fragments of the outer cell wall of Gram-negative bacteria. They

Endpoint — the outcome a trial measures. (Ch.5)

Endpoint mismatch — The situation in which a body of evidence is real and rigorous but measured

Enkephalin — either of two pentapeptides, met-enkephalin (Tyr-Gly-Gly-Phe-Met) and leu-enkephalin

Enteroendocrine cell — a hormone-secreting cell scattered through the intestinal lining, sensing gut contents at its luminal surface and releasing hormones into the bloodstream at its base. (Ch.7)

Epistemic laundering — assembling a claim from individually defensible components so that no single participant has stated it while collectively it has been communicated. (Ch.6)

Epitope [NEW] — the specific portion of an antigen that an immune receptor actually contacts.

Erythropoietic protoporphyria (EPP) — A rare inherited disorder of heme synthesis, most often from

Essentially a copy — a compounded product that duplicates a commercially available approved drug; generally restricted outside defined circumstances such as a shortage (Ch. 38).

Estimand — the precise quantity a trial analysis estimates; it determines whether participants who discontinued are counted, and therefore which of two correct figures a trial reports. (Ch.5)

event-triggered review — The practice of revisiting an entry when a specific event occurs — a

evidence absent — The state of knowledge behind an ❌ where adequate human trials were never run.

evidence absent vs. evidence present and negative — (reprise) The two kinds of ❌. The first

evidence dossier — A personal, maintained reference on a small set of compounds, organized by

evidence present and negative — The state of knowledge behind an ❌ where adequate human trials

Excipient — An inactive formulation ingredient: bulking agent, buffer, stabilizer, preservative.

Exenatide — synthetic exendin-4, approved in 2005 as the first GLP-1 receptor agonist. *(Ch 7

Exendin-4 — a peptide identified in the venom of the Gila monster (Heloderma suspectum), work

expression system — The host organism and genetic machinery used in recombinant production;

Externality — A cost or benefit falling on someone other than the parties to a transaction. Food

Extra-label use — Administration of a drug in a manner not described on its approved label; the

Extracellular matrix (ECM) — The structural network outside cells; in dermis, principally collagen

F

Face validity — The degree to which an animal model superficially resembles the human condition

Facial volume loss — Reduction of fat in the discrete compartments of the face following substantial weight loss, producing hollowing and apparent aging. Occurs after weight loss by any mechanism; magnitude and rate matter, mechanism does not. (Ch.41)

Falsifiability — the property of a claim that specifies what observation would show it to be false; required by rating rule 5, and absent from essentially every claim this book teaches you to distrust.

falsifiability (of a dossier entry) — The property of an entry that specifies, in advance, what

falsifiability (of a rating) — The property, required of every rating in this book, that the

Falsifiable condition — A statement that would have to hold for a scenario to occur, expressed so

Falsifiable prediction — an expectation specific enough to be wrong, with a magnitude and a date

Falsifier — the specific, pre-specified observation that would change a rating. A rating without one is a position rather than a scientific claim. (Ch.17)

Fc fusion — Genetic fusion of a peptide to the constant fragment of an antibody, conferring large

FcRn (neonatal Fc receptor) — The salvage receptor that binds IgG Fc in acidified endosomes and

Feed conversion ratio (FCR) — Kilograms of feed consumed per kilogram of body mass gained. The

Fibroblast — The dermal cell that produces and maintains collagen, elastin, and other matrix

Field 12 check — The audit check requiring every entry to be falsifiable. Its operational test:

Fill-finish — The manufacturing stage in which sterile drug product is filled into its final container. Capital-intensive, heavily regulated, slow to expand, and the binding constraint during the GLP-1 shortage. (Ch.12)

First-pass metabolism — clearance by the liver of drug absorbed from the gut, before it reaches the general circulation. (Ch.4)

Flare — The transient surge of hormone release preceding suppression when a pulsatile axis is stimulated continuously by a receptor agonist; clinically recognized and managed for in GnRH agonist therapy. (Ch.15)

FLOW — the randomized outcomes trial of semaglutide in adults with type 2 diabetes and chronic kidney disease, stopped early for efficacy. (Ch.10)

Fmoc (9-fluorenylmethyloxycarbonyl) — The base-removable N-terminal protecting group used in the

Follistatin — An endogenous secreted glycoprotein of roughly 35–40 kDa that binds and inhibits

Follistatin-344 — A gray-market compound named for the 344-residue follistatin precursor isoform.

Food noise — a patient-derived term for intrusive, persistent background preoccupation with food; frequently reported to quiet on GLP-1 receptor agonists, and currently lacking a validated measurement instrument. (Ch.7)

Forecast — a statement about the future that names what would prove it wrong and can therefore be graded, as distinct from a prediction, which merely asserts and can never be scored.

Formulary — The list of drugs a health plan covers, and the terms on which it covers them. (Ch.12)

Forty-amino-acid line — the United States regulatory threshold separating drugs from biological products: more than 40 amino acids in a specific, defined alpha-amino-acid polymer is a biologic; 40 or fewer is a drug. It determines the follow-on competition pathway (Ch. 38).

Fragment (peptide) — A short peptide corresponding to a portion of a larger parent molecule.

fragment condensation — Building a long peptide by synthesizing and purifying shorter pieces

Franz diffusion cell — An apparatus mounting excised skin between donor and receptor chambers to

Functional endpoint — A measurement of what a person can actually do: gait speed, chair-stand time,

G

G protein — an intracellular molecular switch activated by a GPCR, which then activates effector enzymes. (Ch.2)

G-actin — The free, unpolymerized ("globular") form of actin, as distinct from the polymerized

G-protein-coupled receptor (GPCR) — the largest family of membrane receptors, spanning the cell membrane seven times; the target of most peptide drugs and roughly a third of all approved drugs. (Ch.2)

Gastric emptying — the rate at which stomach contents pass into the small intestine; slowed by GLP-1, flattening the post-meal glucose rise and producing the class's characteristic nausea. (Ch.7)

Gastroparesis — severely delayed gastric emptying; for GLP-1 receptor agonists, the intended mechanism at its extreme rather than an unrelated adverse event. (Ch.8)

GDF-11 — A TGF-β superfamily member closely related to myostatin, signaling through the same type

Generic — a follow-on version of an approved drug, approved through an abbreviated application resting on demonstrated bioequivalence rather than repeated clinical trials (Ch. 38).

Generic name — The single internationally assigned name for a molecule, identical across countries and across every product containing it. Assigned under INN/USAN convention using informative stems. (Ch.41)

Genericide — The trademark-law endpoint of genericization, in which a mark becomes the common name for its category and loses legal protection. Aspirin, escalator, and thermos are completed cases. (Ch.41)

Genericization — The process by which a brand name becomes the common noun for an entire product category. Harmless when one word maps to one molecule; harmful when one word covers multiple non-interchangeable products. (Ch.41)

generous drift — See directional bias. Fingerprint: rating ⚠️ where the evidence supports ❌,

Gepant — a small-molecule CGRP receptor antagonist (ubrogepant, rimegepant, atogepant, zavegepant).

GH axis — the growth hormone axis: GHRH (stimulating) and somatostatin (inhibiting) to growth hormone to IGF-1. (Ch.3)

GHK / GHK-Cu — Glycyl-histidyl-lysine, a naturally occurring tripeptide (~340 Da) first isolated

Ghrelin — a stomach-derived peptide that rises before meals and stimulates appetite; the only substantially orexigenic gut hormone known. (Ch.13)

Ghrelin receptor (GHS-R) — The growth hormone secretagogue receptor; molecular target of GHRP-2, GHRP-6, ipamorelin, and MK-677. Characterized before its natural ligand was identified, which is the origin of its clunky name. (Ch.15)

GHRH (growth hormone releasing hormone) — A hypothalamic peptide that stimulates growth hormone release from the pituitary. The accelerator of the GH axis. (Ch.14)

GHRH (growth hormone-releasing hormone) — The hypothalamic hormone that stimulates pituitary growth hormone release; the accelerator of the GH axis. Native human GHRH is 44 amino acids, with biological activity residing in the first 29. (Ch.15)

GHRH receptor — The pituitary receptor for GHRH, and the molecular target of sermorelin, CJC-1295, and tesamorelin. (Ch.15)

GHRH(1-29) — The first 29 residues of native GHRH, sufficient to activate the GHRH receptor; the scaffold on which essentially every GHRH analog is built. (Ch.15)

GHRP (growth hormone releasing peptide) — The family of peptides acting at the ghrelin receptor. GHRP-6 and GHRP-2 are the historical prototypes. (Ch.15)

Gigantism — Growth hormone excess beginning before the growth plates close, producing extreme stature because the long bones can still lengthen. (Ch.14)

GIP (glucose-dependent insulinotropic polypeptide) — a 42-amino-acid incretin from K cells; probably the larger contributor to the incretin effect in health, substantially blunted in type 2 diabetes, and with an unresolved role in obesity pharmacology. (Ch.7)

Glucagon — a 29-amino-acid peptide hormone from pancreatic alpha cells, cut from the proglucagon

Glucose-dependence — the property, characteristic of incretin action, whereby insulin secretion is amplified only when blood glucose is elevated; the main reason GLP-1 receptor agonists rarely cause hypoglycemia alone. (Ch.3)

GLUT4 — the glucose transporter that relocates to the cell membrane in response to insulin, allowing glucose entry into muscle and fat cells. (Ch.11)

Glycopeptide — A peptide bearing attached sugar groups. Vancomycin and teicoplanin are

GMP (Good Manufacturing Practice) — The enforceable framework of standards governing

GnRH (gonadotropin-releasing hormone) — The hypothalamic hormone whose pulsatile release into the

GnRH agonist — A stabilized analog of gonadotropin-releasing hormone that, delivered continuously,

GnRH antagonist — A molecule that blocks the GnRH receptor directly, producing suppression without

Gray market — trade in compounds sold without approval for human use, typically labeled "research use only"; carries identity, purity, potency, sterility, and endotoxin risks entirely independent of the molecule's pharmacology. (Ch.17; owned by Ch.19)

Growth hormone (GH) — A 191-amino-acid, approximately 22 kDa single-chain peptide hormone secreted by somatotroph cells of the anterior pituitary. Acts directly on target tissues and indirectly through IGF-1. (Ch.14)

Growth hormone deficiency (GHD) — Inadequate growth hormone production. In children it presents as growth failure; in adults as a characterized syndrome of increased central fat, reduced lean mass, reduced bone mineral density, adverse lipids, reduced exercise capacity, and impaired quality of life. (Ch.14)

Growth hormone secretagogue — Any compound that stimulates the pituitary to release growth hormone rather than supplying growth hormone itself. Includes GHRH analogs, ghrelin receptor agonists, and non-peptide molecules such as MK-677. (Ch.15)

Growth promotion — Intervening to increase growth rate or feed efficiency in food animals. An

Guanylate cyclase-C agonist — a drug that activates the guanylate cyclase-C receptor on the luminal

Guanylyl cyclase (particulate) — the enzyme activity built into the intracellular domain of NPR-A

Gut-brain axis — the bidirectional signaling between gastrointestinal tract and central nervous system, carried by hormones, neural pathways, and other routes. (Ch.7)

H

Half-life — the time required for the concentration of a drug in the body to fall by half; the most useful single predictor of a drug's behavior. (Ch.4)

Hard endpoint — an outcome that matters directly to a patient: death, heart attack, stroke, hospitalization, fracture. (Ch.5)

Hazard ratio — the rate of events in the treated group relative to the control group; 0.80 means events occurred at 80% of the control rate, a 20% relative reduction. (Ch.5)

Head-to-head trial — a trial comparing two active treatments directly rather than either against placebo; comparatively rare, and valuable when the comparator is used at an appropriate dose. (Ch.9)

Health equity — The absence of avoidable, unjust differences in health and in access to care

Healthy adherer effect — the observation that people who take medication consistently have better outcomes than those who do not, including when the medication is placebo. (Ch.10)

Helical wheel — A representation of an α-helix viewed down its axis, used to reveal whether

Hemolysis — Lysis of red blood cells, measured by incubating a peptide with erythrocytes and

Hepatorenal syndrome — kidney failure occurring in advanced liver disease, driven substantially by

Hereditary angioedema (HAE) — a genetic disorder of episodic bradykinin-mediated deep tissue

Hexamer — the six-molecule zinc-coordinated complex insulin forms at storage concentrations; inactive, and must dissociate into monomers before the molecule can bind its receptor. (Ch.11)

HFpEF (heart failure with preserved ejection fraction) — heart failure in which the pumping fraction is normal but the heart fills poorly; roughly half of heart failure cases, strongly associated with obesity. (Ch.10)

HFrEF (heart failure with reduced ejection fraction) — heart failure with a reduced ejection

HIV-associated lipodystrophy — A redistribution of body fat seen in people living with HIV, characterized by peripheral subcutaneous fat loss and visceral fat accumulation. The population in which tesamorelin was tested and approved. (Ch.15)

HLA (human leukocyte antigen) [NEW] — the human MHC. Classical class I: HLA-A, -B, -C.

HLA loss of heterozygosity [NEW] — a tumor's loss of one inherited set of HLA genes; a

HLA restriction [NEW] — a T cell recognizes its peptide only when presented by a particular HLA

Homeostasis — maintenance of internal conditions within a narrow range despite external change. (Ch.3)

Host defense peptide — Alternative term for an antimicrobial peptide, preferred where

HPA axis — the hypothalamic-pituitary-adrenal axis: CRH to ACTH to cortisol; the stress axis. (Ch.3)

HPG axis — the hypothalamic-pituitary-gonadal axis: GnRH to LH and FSH to sex steroids. (Ch.3)

HPT axis — the hypothalamic-pituitary-thyroid axis: TRH to TSH to thyroid hormone. (Ch.3)

Human equivalent dose (HED) — An animal dose divided by a species-specific correction factor.

Hydrodynamic radius — The effective size a molecule presents to a filter, including its associated

Hydrolysis — the reverse of condensation: a bond broken by the addition of water. Digestive proteases hydrolyze peptide bonds, which is why most peptides cannot be swallowed. (Ch.1)

Hype cycle — the predictable five-stage progression by which a real preclinical result becomes a commercial claim, losing qualifying information at each transition and requiring no dishonesty from any participant. (Ch.6)

Hyperplasia — An increase in the number of muscle fibers. Largely a developmental phenomenon in

Hypertrophy (muscle) — Growth of existing muscle fibers. The dominant and probably near-exclusive

Hypoactive sexual desire disorder (HSDD) — Persistently low or absent sexual desire causing marked

Hypoglycemia — blood glucose below the level the brain requires; insulin therapy's defining risk, progressing from tremor and confusion to seizure, coma, and death within an hour. (Ch.11)

Hypoglycemia unawareness — loss of the adrenergic warning symptoms of falling blood glucose, common in long-standing type 1 diabetes and dangerous because the warning system has failed. (Ch.11)

Hypogonadotropic hypogonadism — Gonadal failure secondary to inadequate upstream signaling from

Hyponatremia — Abnormally low blood sodium. A documented complication of high-dose oxytocin

Hypothalamus — the brain region that integrates neural, environmental, and metabolic input and converts it into hormone release; the top tier of every endocrine axis. (Ch.3)

I

Icatibant — a synthetic decapeptide antagonist at the bradykinin B2 receptor, approved for acute

IGF binding protein (IGFBP) — One of six proteins that bind circulating IGF-1. Together with the

IGF-1 (insulin-like growth factor 1) — A peptide of about 70 amino acids, structurally similar to proinsulin, produced largely in the liver in response to growth hormone and also locally in many tissues. Mediates most of growth hormone's growth effects and provides negative feedback to the pituitary. (Ch.14)

IGF-1 LR3 (Long R3 IGF-1) — A modified IGF-1 variant carrying a thirteen-residue N-terminal

IGFBP (IGF binding protein) — A carrier protein, principally IGFBP-3, that binds circulating IGF-1 and greatly extends its circulating lifetime. This is why IGF-1 is stable enough to be measured usefully while growth hormone itself is not. (Ch.14)

Ileal brake — the slowing of gastrointestinal transit triggered when nutrients reach the distal small intestine, mediated in part by GLP-1. (Ch.7)

Immortal time bias — a bias arising from misclassifying time during which a patient could not have experienced the outcome. (Ch.10)

Immunogen [NEW] — an antigen that in practice provokes a response. Not all antigens are

Immunogenicity — the tendency of a drug to provoke an immune response against itself. (Ch.4)

Immunological memory [NEW] — the persistent population of antigen-experienced cells left after

Immunomodulator — A compound that alters immune function. A legitimate pharmacological category

In-group favoritism — Preferential treatment of members of one's own group; reported experimentally

INCI name — International Nomenclature of Cosmetic Ingredients; the naming system used for cosmetic ingredients, which describes modification and length rather than identifying a characterized drug substance. (Ch.1)

inclusion body — A dense intracellular aggregate of misfolded protein formed when a host organism

Incretin — a gut hormone released in response to nutrients that amplifies insulin secretion; GLP-1 and GIP are the principal human incretins. (Ch.3)

Incretin effect — the observation that a given blood glucose level produces substantially more insulin secretion when the glucose was taken orally than when infused intravenously. (Ch.3)

Index test — In a diagnostic accuracy study, the test being evaluated. Visual inspection of a photograph would be the index test in the study §41.3 describes and that does not exist. (Ch.41)

Indication — the specific approved use of a drug as stated on its label, which is frequently narrower than the range of situations in which it is prescribed. (Ch.8)

Indication expansion — the process by which a drug approved for one use accumulates evidence and subsequent approvals for others. (Ch.10)

Induced fit — the model in which ligand and receptor both adjust their shapes on binding, rather than fitting together as rigid complementary forms. (Ch.2)

Information asymmetry — the imbalance between what a seller knows about a product and what a buyer can find out. (Ch.6)

Innate immunity — The fast, genetically encoded, non-specific arm of host defense that requires

Insulin analog — an insulin engineered with substitutions or modifications that alter its absorption profile and duration of action. (Ch.11)

Insulin receptor — a receptor tyrosine kinase rather than a GPCR; ligand binding brings the receptor halves together, triggering autophosphorylation and a downstream cascade. (Ch.11)

Insulin resistance — reduced tissue responsiveness to insulin, requiring higher concentrations for the same effect; the core defect in type 2 diabetes. (Ch.11)

Insulin-like growth factor 1 (IGF-1) — A 70-amino-acid single-chain polypeptide structurally related

Insulinotropic — stimulating or amplifying insulin secretion. (Ch.7)

Intention-to-treat — analyzing participants in the group they were randomized to, regardless of what they actually received. (Ch.5)

Intercellular route — Penetration by winding through the lipid matrix between corneocytes; the

Interchangeability — an additional determination beyond biosimilarity, bearing on whether a product may be substituted at the pharmacy level without prescriber involvement (Ch. 38).

internal audit — Checking a dossier against itself for consistency of standard, as distinct from

Interrupted time series — A quasi-experimental design that looks for a break in an existing trend

Intranasal administration — Delivery via the nasal cavity. The route used in nearly all human

Intrathecal — administered directly into cerebrospinal fluid, bypassing the blood-brain barrier.

Intrathecal administration — delivery directly into the cerebrospinal fluid, typically by

Intrinsically disordered — describing a protein or region that does not adopt a single stable

Inverse agonist — a ligand that reduces receptor activity below its resting baseline. (Ch.2)

Inverse care law — The observation, described in 1971, that the availability of good medical care tends to vary inversely with the need for it in the population served. (Ch.12)

Investigational New Drug application (IND) — the filing that permits administration of an investigational compound to human beings. A permission to test, not an approval of anything (Ch. 38).

Ipamorelin — A pentapeptide ghrelin receptor agonist designed for selective growth hormone release. No completed outcome trials exist for the claims it is sold for. (Ch.15)

Isoelectric point — the pH at which a molecule carries no net charge and is least soluble; shifting it is the mechanism by which insulin glargine precipitates at the injection site. (Ch.11)

J

Justification tax — This book's term for the social cost borne by people who must explain an approved prescription to strangers, colleagues, or family because the culture has coded the whole drug class as elective. Not a pharmacological cost. (Ch.41)

K

K cell — the enteroendocrine cell that produces GIP, concentrated in the upper small intestine. (Ch.7)

Kappa receptor (κ, OPRK1) — an inhibitory GPCR opioid receptor preferred by the dynorphins.

KISS1R — The kisspeptin receptor. Loss-of-function mutations cause failure of puberty, which is

Kisspeptin — A hypothalamic peptide encoded by the KISS1 gene, acting through KISS1R upstream of

KPV — The tripeptide lysine-proline-valine, corresponding to the C-terminal fragment of α-MSH,

L

L cell — the enteroendocrine cell that produces GLP-1, concentrated in the distal small intestine and colon. (Ch.7)

Label (approved label) — the reviewed document accompanying an approved drug describing the approved use, the population studied, dosing evaluated, adverse events observed, and required warnings. It records what was submitted and approved, not what is known (Ch. 38).

Lactam bridge — An amide bond formed between two amino acid side chains (here, an aspartate and a

Larazotide — An octapeptide studied for celiac disease as a tight junction regulator. Taken orally

Laron syndrome — Inherited insensitivity to growth hormone at its receptor, producing very low IGF-1 signaling for a lifetime and short stature. Studied cohorts have been reported to show remarkably low rates of diabetes and cancer. The mirror-image natural experiment to acromegaly. (Ch.14)

Laron syndrome (GH receptor deficiency) — An inherited defect in GH receptor signaling producing

Lean mass — non-fat body mass, including muscle; a surrogate for strength and physical function rather than a substitute for measuring them. (Ch.8)

Legal fiction — a formally maintained characterization that all parties understand does not describe the actual transaction. (Ch.6)

Leptin — a hormone produced by adipose tissue in proportion to fat mass, signaling stored energy availability to the hypothalamus; the discovery that established fat as an endocrine organ. (Ch.13)

Leptin resistance — reduced responsiveness to leptin despite elevated circulating levels; the state characterizing common obesity, and the reason leptin failed as a general therapy. (Ch.13)

Ligand — any molecule that binds a receptor. A peptide acting on its receptor is a ligand. (Ch.2)

Linaclotide — a 14-amino-acid guanylate cyclase-C agonist, taken orally and designed for minimal

Line of therapy — Where a treatment sits in a sequence: first-line, or after specified prior

Linear epitope [NEW] — a contiguous stretch of amino acid sequence recognized by a T cell after

linker — The chemical connector between resin and peptide chain, chosen to hold reliably through

Lipid A — The membrane-anchoring portion of lipopolysaccharide; the site modified by

Lipid matrix — The ceramide-, cholesterol-, and free-fatty-acid-rich "mortar" between corneocytes.

Lipid nanoparticle [NEW] — the mRNA delivery vehicle; simultaneously carrier and a substantial

Lipidation — the attachment of a fatty acid to a peptide, typically to enable albumin binding and extend half-life. (Ch.4)

Lipolysis — Breakdown of stored triglyceride in adipose tissue with release of free fatty acids. A direct growth hormone effect and the main reason fat mass falls when growth hormone is administered. (Ch.14)

Lipopeptide — A peptide bearing a covalently attached lipid tail. Colistin, polymyxin B, and

Lipopolysaccharide (LPS) — The major constituent of the Gram-negative outer leaflet. Its lipid A

List price (WAC) — The price a manufacturer publishes for a product. Public, paid by almost nobody with insurance, and the number that appears in headlines. (Ch.12)

LL-37 — The human cathelicidin antimicrobial peptide. Has direct membrane-disrupting antibacterial

lyophilization — Freeze-drying; the usual final isolation step for a peptide, producing a

Lysyl oxidase — The copper-dependent enzyme that cross-links collagen and elastin fibers. The

M

MACE — major adverse cardiovascular events; a composite endpoint typically comprising cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke. (Ch.5)

Magainin — An α-helical antimicrobial peptide isolated from the skin of Xenopus laevis and

Magainins — antimicrobial peptides identified in the skin of the African clawed frog (*Xenopus

Magnocellular neuron — Large hypothalamic neurons (paraventricular and supraoptic nuclei) that

Market entry reward — A proposed lump-sum payment on approval of a qualifying novel antibiotic,

Marketing authorization — the term used in the European Union and elsewhere for what United States practice calls an approval (Ch. 38).

MASH (metabolic dysfunction-associated steatohepatitis) — the inflammatory, progressive form of MASLD, which can advance to fibrosis and cirrhosis; formerly called NASH. (Ch.10)

MASLD (metabolic dysfunction-associated steatotic liver disease) — fat accumulation in the liver associated with metabolic dysfunction; formerly called NAFLD. (Ch.10)

Mass spectrometry (MS) — an analytical technique measuring the mass-to-charge ratio of ions. A

Mass-to-charge ratio (m/z) — the quantity a mass spectrometer actually measures. Because peptides

master table — The reference table in Chapter 37 §37.5 reproducing all 140 molecule-and-indication

Matrix metalloproteinase (MMP) — An enzyme that degrades extracellular matrix proteins;

MC1R — The melanocortin receptor expressed on melanocytes. Activation shifts pigment production

MC3R / MC4R — Central nervous system melanocortin receptors involved in energy balance and in

MC4R (melanocortin-4 receptor) — the receptor at which the appetite circuit's accelerator and brake converge; the most common known monogenic contributor to obesity. (Ch.13)

mcr — A family of plasmid-borne genes encoding phosphoethanolamine transferases that modify lipid

Mecasermin — Recombinant human IGF-1, approved for severe primary IGF-1 deficiency in children and

Mechanotransduction — The conversion of mechanical deformation of structural proteins into

Medicalization — The process by which a human variation or difficulty comes to be described,

Medullary thyroid carcinoma — a rare thyroid cancer arising from C-cells; the subject of the GLP-1 agonist class boxed warning, based on rodent findings not demonstrated in humans. (Ch.8)

Melanocortin — The family of peptides derived from proopiomelanocortin, including α-MSH and ACTH,

Melanocortin receptor — A family of five G-protein-coupled receptors, MC1R through MC5R, differing

Melanocortin system — the hypothalamic circuit in which α-MSH activates and AgRP blocks the MC4R receptor, setting appetite; the convergence point of the leptin signal. (Ch.13)

Melanocytic nevus — A mole; a benign localized proliferation of melanocytes. Changes in existing

Melanotan II — An unapproved cyclic melanocortin agonist, structurally very close to bremelanotide

MEN2 (multiple endocrine neoplasia type 2) — an inherited syndrome carrying high medullary thyroid carcinoma risk; a contraindication to GLP-1 receptor agonist therapy. (Ch.8)

Message-address — the organizing description of endogenous opioid peptide structure: a shared

Meta-analysis — a statistical pooling of results from multiple studies. (Ch.5)

Metabolic adaptation — The fall in energy expenditure following weight loss, beyond what the loss of tissue mass alone predicts. Part of the body's defense of a set point. (Ch.12)

Metabolic memory (legacy effect) — the observation that a period of good glycemic control appears to confer durable benefit after the period ends; named from an observational extension, and not mechanistically established. (Ch.11)

MHC (major histocompatibility complex) [NEW] — the family of cell-surface molecules that

Microneedling — Physical puncture of the skin barrier with fine needles. Unambiguously effective

Milk ejection reflex — Neuroendocrine arc in which suckling or infant cues trigger pulsatile

Minimal clinically important difference (MCID) — the smallest change in an outcome measure that patients perceive as meaningful; a statistically significant difference below the MCID is a finding about biology, not a reason to act. (Ch.17)

Minimum inhibitory concentration (MIC) — The lowest concentration of an agent preventing visible

Misattribution — Assigning a result to a cause that did not produce it. Distinguished from non-disclosure: silence makes no claim, misattribution makes a false one and is therefore subject to ordinary evidence evaluation. (Ch.41)

MK-677 (ibutamoren) — An orally active, long-acting ghrelin receptor agonist that is not a peptide. Reliably raises GH and IGF-1 in humans and carries a documented signal for increased blood glucose and reduced insulin sensitivity. Not approved. (Ch.15)

modality versus product — The distinction between an intervention type with a clinical literature

Model organism — A species studied as a stand-in for another, chosen for tractability and

Monitoring (reinforced) — baseline and interval measurement aimed at detecting specific

Monogenic obesity — severe, early-onset obesity caused by a single gene defect, identifiable by molecular diagnosis. (Ch.13)

Monograph — a pharmacopeial document specifying what a substance must be and what it must meet,

Monoisotopic mass — a molecule's mass calculated using the most abundant isotope of each element.

Monopsony — A market with a single dominant buyer; the buyer-side mirror of monopoly. The mechanism by which national health systems obtain lower drug prices. (Ch.12)

Motivated reasoning — reasoning shaped by a preferred conclusion; invisible from inside, and indistinguishable from hope when experienced. (Ch.6)

mRNA display — a cell-free selection technology in which a peptide is covalently linked to its

Mu receptor (μ, OPRM1) — the inhibitory GPCR opioid receptor responsible for the analgesia,

Multi-agonist — A single molecule that activates more than one receptor, in a ratio fixed by its

Multidrug-resistant (MDR) — Descriptor for an organism non-susceptible to agents in multiple

Myonuclear domain — The volume of cytoplasm governed by a single nucleus within a multinucleated

Myostatin — a negative regulator of skeletal muscle mass signaling through the activin type II receptors; blocking myostatin or those receptors increases muscle mass in animal models (Chapter 16), which is the rationale behind the agents in §36.6.

Myostatin (GDF-8) — A TGF-β superfamily member produced and secreted by skeletal muscle that acts

N

N-methylation — addition of a methyl group to a peptide backbone amide nitrogen. Reduces protease

n-of-1 — an observation in a single individual; compelling as narrative and near-worthless as evidence of efficacy, because a single uncontrolled case cannot distinguish treatment from natural recovery, expectation, or regression to the mean. (Ch.6)

N-terminus — the end of a peptide chain bearing a free amino group. Sequences are written and numbered from here by universal convention. (Ch.1)

Naloxone — a short-acting competitive opioid receptor antagonist. Used clinically to reverse

Naltrexone — a longer-acting opioid receptor antagonist used clinically and in research. — Ch 20

Narcolepsy type 1 — narcolepsy with cataplexy, caused by loss of orexin-producing neurons, most

native chemical ligation — A method, introduced in the mid-1990s, for joining two unprotected

Natriuresis — excretion of sodium in the urine. The accompanying water loss is diuresis. [Ch 28]

Natriuretic peptide — a peptide released by cardiac muscle in response to stretch, promoting sodium and water excretion and vasodilation; ANP and BNP are the principal ones. (Ch.3)

Natriuretic peptide resistance — the observation that in established heart failure, circulating

Natural experiment — A situation in which something approximating random assignment occurred by

Natural history — the course a condition would take without treatment; the comparison an individual case has no access to. (Ch.6)

Negative feedback — regulation in which a system's output inhibits its own production, holding a variable near a set point. (Ch.3)

Neoantigen [NEW] — a peptide containing an amino acid change produced by a somatic mutation,

Neprilysin — an ectopeptidase that degrades enkephalins among other peptides; the principal

Nesiritide — recombinant human BNP, administered by infusion. Approved for acute decompensated

Net price — What a health plan actually pays for a drug after confidential rebates and fees are applied. Not public. (Ch.12)

Net protein balance — The running difference between muscle protein synthesis and muscle protein

Neurodiversity — The view that variations in neurological development, including autism, are

Neuroendocrine tumor (NET) — A tumor arising from hormone-producing cells, most often in the gut,

Neuromodulator — a signaling molecule that changes how a neuron responds to other signals rather than directly exciting or inhibiting it; most neuropeptides act this way. (Ch.2)

Neuromuscular junction — The synapse between a motor nerve terminal and a muscle fiber. It lies

Neuropeptide — a short amino acid chain used as a signaling molecule between neurons, acting on

Neuropeptide Y (NPY) — a 36-residue peptide, among the most abundant neuropeptides in the mammalian

Neurotransmitter — a signaling molecule released across a synapse that directly excites or inhibits the receiving neuron. (Ch.2)

Neurotransmitter-inhibiting peptide — A cosmetic peptide proposed to reduce acetylcholine release,

New Drug Application (NDA) — the United States application type for a drug, including peptides of 40 or fewer amino acids (Ch. 38).

NK1 receptor — the tachykinin GPCR preferred by substance P. Target of an antagonist class that

Nocebo — the mirror of the placebo phenomenon, in which negative expectation worsens symptoms. In

Nociceptin / orphanin FQ — a 17-residue peptide structurally related to the opioid peptides but

Nociception — the neural detection and transmission of potentially damaging stimuli. Distinct from

Non-approved substances (WADA S0) — Prohibited-List category covering any pharmacological

Non-inferiority trial — a design asking whether a treatment is not meaningfully worse than its comparator, rather than whether it is better. (Ch.9)

Non-proteinogenic — Not encoded by the genetic code, and therefore not incorporable by ribosomal

Nonapeptide — A peptide nine amino acids long. Oxytocin and vasopressin are the canonical examples;

Nose-to-brain transport — Proposed movement of molecules from the nasal cavity into the brain along

NOT RATED — A claim the rating system declines to rate because it is not the kind of claim that

NPR-A / NPR-B / NPR-C — the natriuretic peptide receptors. NPR-A binds ANP and BNP; NPR-B binds

NT-proBNP — the 76-amino-acid N-terminal fragment released when proBNP is cleaved. Biologically

Nucleus tractus solitarius (NTS) — the hindbrain nucleus that receives vagal sensory input and integrates it with circulating signals. (Ch.7)

null revision — A dated dossier revision recording that news arrived and the rating did not move.

Number needed to treat (NNT) — how many people must receive a treatment for one additional person to benefit; the most honest single number in medicine. (Ch.5)

O

ob/ob mouse — the leptin-deficient mouse strain whose study led to leptin's identification; a model of leptin deficiency rather than of common obesity. (Ch.13)

Obstructive sleep apnea — repeated collapse of the upper airway during sleep, strongly associated with obesity. (Ch.10)

Occlusion — Covering skin to reduce water loss. Hydrates the stratum corneum, increases penetration

Off-label (reinforced) — prescribing an approved drug for an indication, population, or route not

Off-label prescribing — a licensed prescriber's use of an approved drug for an unapproved indication; lawful in the United States and many other jurisdictions, and silent on the state of the evidence (Ch. 38).

Off-label promotion — a manufacturer's marketing of a drug for an unapproved use; generally prohibited. The asymmetry with prescribing is deliberate (Ch. 38).

Off-label use — Prescribing an approved drug outside its approved indication, population, dose, or route. Legal in the US, common, often the standard of care, and it shifts evidentiary responsibility to the prescriber. Not the same as unapproved. (Ch.12)

Oligopeptide — a short peptide, conventionally under about 20 residues. (Ch.1)

Opioid-induced hyperalgesia — increased pain sensitivity arising from sustained opioid exposure,

Orexigenic — appetite-stimulating. (Ch.13)

Orexin (hypocretin) — two peptides, orexin-A and orexin-B, produced from a single precursor by

Orforglipron — an investigational oral small-molecule GLP-1 receptor agonist; notable for not being a peptide, and therefore escaping the delivery and manufacturing constraints of the peptide agonists. (Ch.9)

Orphan compound — a molecule that cannot be profitably developed because it is unpatentable, cheap, or off-patent, regardless of scientific merit; the structural reason many answerable questions stay unanswered. (Ch.17; concept introduced Ch.5)

Orthogonal methods — analytical methods whose separation or detection principles are independent,

Out-of-pocket cost — What a covered patient actually pays at the counter, determined by plan design rather than by the drug's price. (Ch.12)

Outcome switching — reporting a secondary measure as though it were the trial's question, after the pre-specified primary endpoint disappointed. (Ch.5)

Overall survival (OS) — Time until death from any cause. The hardest endpoint in oncology, and one

Oxytocin — A nonapeptide hormone synthesized in the hypothalamus and released from the posterior

Oxytocin receptor (OXTR) — The single known human receptor for oxytocin; a G-protein-coupled

P

P-value — the probability of observing a result at least this extreme if the treatment had no effect; below 0.05 is conventionally called statistically significant. (Ch.5)

Pair bond — A durable selective social attachment between two adults. Measured in voles as partner

Palmitoyl pentapeptide-4 — A five-residue fragment of type I procollagen carrying an attached

Palmitoylation — Attachment of a 16-carbon fatty acid to a peptide, increasing lipid solubility. In

Panning — the selection step of a display experiment: washing a library over an immobilized

Parabiosis — an experimental technique joining the circulations of two animals, used in the 1960s–70s to infer the existence of a circulating satiety factor and of resistance to it. (Ch.13)

Paracrine — signaling to neighboring cells across short distances without entering the bloodstream. (Ch.2)

Parathyroid hormone (PTH) — an 84-residue peptide hormone regulating blood calcium. Continuous

Parenteral — any route of administration bypassing the gastrointestinal tract; in practice, injection. (Ch.4)

Partial agonist — a ligand that activates a receptor submaximally at any dose; it acts as an activator when alone and as an inhibitor in the presence of a full agonist. (Ch.2)

Partner preference — The standard behavioral assay of pair bonding in vole research. (Ch 21 §21.3)

Pattern recognition receptor [NEW] — an innate receptor (e.g. a Toll-like receptor) detecting

Payer churn — The movement of individuals between insurers, plans, and programs over time. Its

PDE5 inhibitor — A class of small-molecule drugs (sildenafil and relatives) acting peripherally to

PEGylation — Covalent attachment of polyethylene glycol chains to a therapeutic molecule. The

Penetration enhancer — A formulation ingredient that increases absorption, typically by disrupting

Pentadecapeptide — a peptide of exactly fifteen residues. BPC-157 is one. (Ch.1)

Peptibody — A construct in which short peptide sequences are grafted onto an antibody Fc domain.

Peptide — conventionally, a chain of roughly 2–50 amino acids joined by peptide bonds. The upper boundary is a convention, not a chemical distinction. (Ch.1)

Peptide bond — the covalent amide link between the carboxyl group of one amino acid and the amino group of the next, formed by a condensation reaction that releases water. (Ch.1)

Peptide content — The fraction of a lyophilized product's total mass that is actually peptide, as

peptide content — The fraction of a preparation's total mass that is actually peptide. A

Peptide engineering — The deliberate chemical modification of a peptide to change its

Peptide receptor radionuclide therapy (PRRT) — Therapy in which a receptor-targeting peptide,

Peptide YY (PYY) — a peptide released from intestinal L cells after meals that reduces subsequent food intake; extensively pursued as a target without producing an approved drug. (Ch.13)

Peptide-drug conjugate — a construct joining a targeting peptide, a linker, and a payload, in which the peptide's job is not to have an effect but to arrive somewhere specific; its receptor selectivity is the delivery address.

Peptide-drug conjugate (PDC) — A targeting peptide joined by a linker to a cytotoxic payload; the

Peptidomimetic — A non-peptide or partly non-peptide molecule designed to reproduce a peptide's

Per-protocol — analyzing only those participants who completed the treatment as assigned. (Ch.5)

Peri-operative — the period surrounding a procedure, including preparation, the procedure itself,

Periaqueductal gray (PAG) — a midbrain region central to descending pain modulation. Receives input

Peripheral tolerance [NEW] — mechanisms, including regulatory T cells, restraining self-reactive

Permeation enhancer — an excipient that transiently promotes absorption of a poorly absorbed drug across a membrane; SNAC in oral semaglutide is the principal example. (Ch.4)

Personal import exemption — A provision in some jurisdictions permitting an individual to import

Phage display — a selection technology in which peptide variants are displayed on the surface of

Pharmacodynamics — what a drug does to the body: receptor binding and the resulting effect. (Ch.4)

Pharmacokinetics — what the body does to a drug: absorption, distribution, metabolism, and excretion. (Ch.4)

Pharmacopeia — an officially recognized compendium of drug standards, such as the United States

pharmacopeial monograph — A published public standard for a specific substance listing required

Pharmacovigilance — The systematic collection, analysis, and action on safety information about

Pharmacy benefit manager (PBM) — An intermediary that negotiates drug prices and manages formularies on behalf of health plans. (Ch.12)

Phase 1 — first-in-human study, usually small and often in healthy volunteers, assessing safety, tolerability, and pharmacokinetics. Generally not designed to demonstrate that the drug helps anyone.

Phase 2 — mid-stage trial assessing efficacy signals and dose at modest sample size, usually on surrogate endpoints; systematically more favorable than the phase 3 that follows, which is phase 2 optimism (Chapter 9).

Phase 2 optimism — the systematic tendency for Phase 2 effect sizes to exceed the Phase 3 results that follow, arising from small samples, best-dose selection, favorable populations, shorter durations, and regression to the mean; requires no misconduct by anyone. (Ch.9)

Phase 3 — the large, adequately powered confirmatory trial regulators rely on, where most of the cost sits and most surprises happen.

Phase 4 — study and monitoring after approval, including post-marketing surveillance and any confirmatory trials required as a condition of approval (Ch. 38).

Phase I — the first stage of human testing, assessing safety and pharmacokinetics in a small number of participants. (Ch.5)

Phase I trial — the first study of a compound in humans, typically dose-escalation in healthy volunteers, producing pharmacokinetics and systematically collected safety data. None exists for BPC-157 in the published literature. (Ch.17)

Phase II — the stage testing for an efficacy signal and dose-response in dozens to a few hundred participants; results are systematically more optimistic than subsequent Phase III findings. (Ch.5)

Phase III — the definitive efficacy stage, in hundreds to tens of thousands of participants in the target population. (Ch.5)

Phase IV — post-marketing surveillance, detecting rare harms and real-world effects after approval. (Ch.5)

Photoaging — The component of visible skin aging caused by ultraviolet exposure, as distinct from

Physical dependence — a state in which the body has adapted to a drug's presence such that abrupt

PIONEER — the clinical development program for oral semaglutide. (Ch.8)

Pipeline — the set of compounds a field has in development, at various stages; readable only with the phase, estimand, dose, population, endpoint, and source of each announcement attached. (Ch.9)

Pituitary — the small gland at the base of the brain that releases tropic hormones into the general circulation in response to hypothalamic signals. (Ch.3)

Placebo — an inactive treatment made indistinguishable from the active one, used as a comparator. (Ch.5)

Placebo analgesia — pain relief produced by an inert intervention together with the expectation of

Plecanatide — a guanylate cyclase-C agonist structurally related to the natural ligand uroguanylin,

Pleiotropic effect — an effect of a drug or gene on multiple apparently unrelated systems or outcomes. (Ch.10)

Polyagonist — a molecule activating three or more receptors; retatrutide, targeting GLP-1, GIP, and glucagon receptors, is an example. (Ch.9)

Polymyxins (polymyxin B, colistin) — cyclic lipopeptide antibiotics used as last-line agents

Polypeptide — a long amino acid chain; used either as a synonym for protein or for a chain that has not folded into a functional structure. (Ch.1)

POMC (proopiomelanocortin) — the precursor protein cleaved to produce α-MSH and other peptides; loss-of-function variants cause severe early-onset obesity. (Ch.13)

population check — The audit check that requires every Field 6 row to name both a population and

Population-level effect — An outcome that emerges only at the scale of a whole population — a

Portal circulation (hypothalamic-pituitary) — the short dedicated vascular connection between hypothalamus and pituitary, delivering releasing hormones at high local concentration without systemic exposure. (Ch.3)

Posterior pituitary — The neural lobe of the pituitary; not a synthesizing gland but the release

Postpartum hemorrhage — Excessive bleeding after delivery, frequently from uterine atony; a leading

Potency — how much of a drug is required to produce a given effect; commonly expressed as EC50. (Ch.2)

Powered — describing a trial large enough that a real effect of the anticipated size would be detected; an underpowered trial finding nothing has told you little. (Ch.5)

PP-fold — the compact hairpin structure shared by NPY, PYY, and pancreatic polypeptide: an extended

Prairie vole — Socially monogamous North American rodent whose contrast with closely related

Pramlintide — a synthetic amylin analog, engineered because native human amylin aggregates; approved as an adjunct to mealtime insulin. (Ch.13)

Preclinical — development conducted before a compound has been given to a human for the indication in question: cells, tissue, animals. Not a synonym for "almost in trials"; it is a different category of knowledge.

Preclinical evidence — research conducted before human testing: cell culture, tissue, and animal studies. It generates candidates and cannot adjudicate them. (Ch.17)

Predatory journal — a publication that prints essentially anything for a fee, without genuine peer review. (Ch.5)

Predictive validity — The degree to which interventions effective in an animal model prove

preparative HPLC — High-performance liquid chromatography run at a scale intended to collect

Preprint — a manuscript posted publicly before peer review; legitimate, useful, and not reviewed. (Ch.5)

Preregistration — Publicly specifying hypotheses, outcomes, and analyses before data collection, so

Primary afferent — a first-order sensory neuron carrying information from the periphery into the

Primary endpoint — the pre-specified main outcome a trial is designed and powered to detect; changing it after the fact is outcome switching. (Ch.5)

Primary structure — the amino acid sequence of a peptide or protein; its information content. (Ch.1)

Prior authorization — A requirement that a prescriber submit documentation and obtain approval before a plan will pay for a drug. A legitimate stewardship tool that also functions as a non-random attrition filter. (Ch.12)

proBNP — the 108-amino-acid precursor cleaved into biologically active BNP and inactive

Process simulation (media fill) — running an entire aseptic filling operation using growth medium

Procollagen — The precursor form of collagen, carrying propeptide extensions cleaved during

Prodynorphin — the precursor protein yielding dynorphin A, dynorphin B, and the neoendorphins. —

Proenkephalin — the precursor protein yielding met-enkephalin (in several copies) and

Profilometry — Measurement of skin surface topography, often from a silicone replica, quantifying

Proglucagon — the precursor protein processed differently in different tissues to yield glucagon in pancreatic alpha cells and GLP-1 in intestinal L cells. (Ch.7)

Progression-free survival (PFS) — Time until the disease is shown to grow or the patient dies. Not

Prohibited List — WADA's annually updated list of prohibited substances and methods, organized into categories (Ch. 38).

Prohibited substance list — A sporting or racing authority's list of substances barred from

proinsulin — Insulin's single-chain precursor, in which a connecting segment (the C-peptide)

Proopiomelanocortin (POMC) — a single precursor protein processed, in a tissue-specific manner,

Prophylactic vaccine [NEW] — given to healthy people to prevent disease. Extremely high safety

Protease — an enzyme that cleaves peptide bonds. Also called a peptidase. Pepsin, trypsin, and chymotrypsin are examples. (Ch.1)

protecting group — A chemical cap on a reactive group that renders it temporarily inert and can be

Protein — conventionally, a chain of roughly 50 or more amino acids, usually folded into a defined functional structure. (Ch.1)

ProteinMPNN — a computational method for the sequence-design half of de novo design: given a

Proteolysis — enzymatic breakdown of peptide bonds, carried out by proteases and peptidases. The default fate of any peptide in the body. (Ch.1)

Prothymosin alpha — The larger precursor protein from which thymosin alpha-1 derives. [ch18 §18.3]

Protopathic bias (reverse causation) — the bias arising when early, undiagnosed disease influences which treatment a patient receives. (Ch.10)

Protoporphyrin IX — The heme precursor that accumulates in erythropoietic protoporphyria; it

Provocation study — a human experiment in which administering a suspected causal agent reproduces

PRRT — peptide receptor radionuclide therapy, the approved existence proof for the conjugate architecture: a somatostatin-analog targeting peptide, a chelator caging a metal ion, and a therapeutic radioisotope (Chapter 27).

PSMA (prostate-specific membrane antigen) — A transmembrane enzyme highly expressed on most

PTH(1–34) — the N-terminal 34-residue fragment of parathyroid hormone, retaining full receptor

PTHrP — parathyroid hormone-related protein, a separate gene product from PTH that acts at the same

Publication bias — the tendency for positive results to be published and negative ones not to be, systematically distorting the apparent evidence base without any individual paper being fraudulent. (Ch.5)

Publication filtering — The process by which a published literature becomes an unrepresentative

Pulsatile secretion — Release of a hormone in discrete bursts rather than continuously. Growth hormone secretion is strongly pulsatile and predominantly nocturnal, falling to near-undetectable levels between bursts, which is why a single random measurement is nearly uninterpretable. (Ch.14)

Pulsatility — release of a hormone in discrete bursts rather than continuously, where the temporal pattern itself carries information. (Ch.3)

purity by peak area — The product peak's integrated area as a percentage of total integrated peak

Q

Quaternary structure — the assembly of two or more separate folded chains into a functional unit; insulin's storage hexamer is an example. (Ch.1)

R

R group — the variable side chain attached to an amino acid's alpha carbon; the only part that differs among the twenty, and therefore the source of all chemical variety in peptides. (Ch.1)

RAAS (renin-angiotensin-aldosterone system) — the hormonal system that raises blood pressure and

racemization — Inversion of a residue's three-dimensional configuration during activation,

Radioligand therapy — The general category PRRT belongs to: a targeting ligand of any chemical

Radionuclide — A radioactive isotope; in therapy, chosen for emissions that damage cells over very

Random coil — a region of peptide with no regular repeating secondary structure. Many short peptides are largely coil in solution and adopt a defined shape only on binding. (Ch.1)

Randomization — assigning trial participants to arms by chance, which makes the groups comparable in every respect including characteristics nobody measured. (Ch.5)

Rate-limiting step — the stage of a process that determines its overall speed. Improving any

rating drift — The movement of a rating over time as evidence accumulates. For a ⚠️ resting on a

Rational design — designing a molecule from knowledge of the target, its physiology, or its

Rebate — A payment from a manufacturer to a plan or pharmacy benefit manager in exchange for formulary placement. Lowers net price for insurers; does nothing for the uninsured. (Ch.12)

Rebound — a temporary overshoot or deficit occurring when a suppressive influence is withdrawn. (Ch.3)

Receptor — a protein that recognizes a specific ligand and changes its behavior in response, converting an external signal into an internal one. (Ch.2)

Receptor downregulation — reduction in the number of receptors on a cell surface following sustained stimulation, occurring over hours to days. (Ch.2)

Receptor subtype selectivity — the property of a ligand that acts preferentially at one receptor

Receptor-mediated transcytosis — active transport of cargo across the blood-brain barrier by an endothelial receptor such as the transferrin receptor, exploited by attaching a therapeutic to a ligand for it so that it rides across as a passenger.

Recombinant — Produced by genetically engineered cells rather than extracted from tissue. Recombinant growth hormone replaced cadaver-derived material in the mid-1980s and removed the supply constraint that had defined the entire field. (Ch.14)

Recombinant DNA — the technique of inserting a gene into a host organism to produce a protein; human insulin, approved in 1982, was the first drug produced this way. (Ch.11)

recombinant DNA production — Inserting the gene for a desired peptide into a host organism,

Redundancy — the presence of multiple overlapping signals serving one function, such that loss of any single signal is largely compensated; the structural reason single-target appetite drugs underperform. (Ch.13)

Reference standard — The independent method that establishes the truth against which an index test is judged. Its unavailability outside a research setting is what makes visual identification of drug use untestable. (Ch.41)

refolding — The process step in which an unfolded or misfolded chain is coaxed into its correct

Regioselectivity — The property of a chemical reaction occurring at one specific site rather than

Regression to the mean — the statistical tendency for extreme measurements to be followed by less extreme ones, which makes any treatment begun when a person feels worst appear to help. (Ch.5)

Regulatory divergence — The situation in which regulators in different jurisdictions reach

Regulatory patchwork — the situation in which agencies applying broadly similar principles reach different conclusions about the same molecule, because of differing evidence standards, sponsor filing decisions, medical context, or timing (Ch. 38).

Regulatory T cell [NEW] — a suppressive T cell; an obstacle in cancer vaccination and a goal in

Related substances — Impurities structurally similar to the intended peptide, arising during

Relative risk reduction — the proportional reduction in risk, expressed as a ratio; systematically more impressive-sounding than the absolute figure. (Ch.5)

Releasing hormone — a hypothalamic peptide that travels via the portal circulation to stimulate pituitary hormone release; CRH, TRH, GnRH, and GHRH are the four principal ones. (Ch.3)

Repeated interaction — a relationship in which the same two parties engage many times, so that

Replacement versus override — The distinction between supplying a hormone that is absent and adding to one being produced normally. Replacement predicts durable benefit; overriding an intact system predicts adaptation, including feedback suppression of endogenous production. (Ch.14)

Replication — Independent repetition of a study to determine whether its finding holds. A published

Research chemical — a compound sold labeled "for research use only" or "not for human consumption," a formulation that avoids drug regulation and liability while permitting a market in human use. (Ch.6)

Research use only — a seller's disclaimer stating that a product is not for human consumption. A liability posture, not a regulatory category conferred by any agency (Ch. 38).

Research use only (RUO) — A designation placing a substance outside the regulatory definition of

Residual payer — The party left holding the undiscounted price because they sit outside the rebate structure. In US drug pricing, typically the uninsured patient. (Ch.12)

Residual solvent — Solvent remaining from synthesis or purification, controlled to defined limits

Residue — an amino acid once incorporated into a chain, so called because it is what remains after the condensation reaction released water. (Ch.1)

Residue tolerance — The maximum permissible concentration of a drug or its metabolites in edible

resin (solid support) — The insoluble polymer beads to which a growing chain is anchored during

Response factor — the relationship between the mass of a compound and the detector signal it

Retatrutide — an investigational triple agonist at the GLP-1, GIP, and glucagon receptors. (Ch.9)

Retention time — the time at which a component emerges from a chromatography column. A property of

RFdiffusion — a computational method that generates plausible protein backbones, including

Ribosome display — a cell-free selection technology in which translation is stalled so that the

right for the wrong reasons — A rating that matches what the evidence supports but was produced by

Rostral ventromedial medulla (RVM) — the brainstem relay of the descending pain-modulatory pathway,

S

S0 (Non-Approved Substances) — the WADA category prohibiting at all times any pharmacological substance not currently approved by any governmental regulatory health authority for human therapeutic use. A rule about a property rather than a list of names (Ch. 38).

S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) — the WADA category covering growth hormone, secretagogues and GHRH analogs, IGF-1 and its analogs, erythropoiesis-affecting agents, and related compounds (Ch. 38).

Salt form — A drug substance paired with a counter-ion. Semaglutide sodium and semaglutide acetate are not the same substance as semaglutide base, and their safety and effectiveness had not been established. (Ch.12)

same-evidence test — The audit check that identifies two entries with comparable evidence bases

Sarcopenia — Age-related loss of muscle mass and function. Contemporary consensus definitions lead

Sarcopenic obesity — the combination of excess adiposity with low muscle mass, typically in older adults; the population in which lean mass loss during weight reduction is of greatest concern and least studied. (Ch.8)

Satellite cell — A resident muscle stem cell lying beneath the fiber's basal lamina that activates

Satiety — the state of fullness that suppresses further eating between meals, as distinct from satiation, which ends a given meal. (Ch.7)

Saturable transport system — a carrier-mediated route across the blood-brain barrier available to

Second messenger — a small intracellular molecule that carries a signal onward after the first messenger has bound outside the cell. (Ch.2)

Second-order effect — A consequence that follows from the response to a thing rather than from the thing itself. Shortage spillover, hardened coverage arguments, and the justification tax are second-order effects of cultural framing, not of pharmacology. (Ch.41)

Secondary structure — local, regular folding of the peptide backbone held together by hydrogen bonds, principally the alpha helix and the beta sheet. (Ch.1)

Secretin — a 27-amino-acid peptide hormone, the first hormone ever identified (Bayliss and

SELECT — the cardiovascular outcomes trial of semaglutide 2.4 mg in adults with established cardiovascular disease and overweight or obesity, without diabetes. (Ch.8)

Selectivity — The degree to which a compound engages its intended receptor and not others. Ipamorelin was designed for selectivity at GHS-R with less of the appetite, cortisol, and prolactin activity associated with GHRP-6. A statement about receptors, not about safety. (Ch.15)

Selectivity index — The ratio of the concentration harming host cells to the concentration

Sentence ladder — the teaching device in Case Study 1: five progressively less accurate one-sentence descriptions of the same study, used to locate the exact step at which a claim stops being licensed. (Ch.17)

Sequence — the order of amino acids in a chain, written N-terminus to C-terminus; equivalently, primary structure. (Ch.1)

Sermorelin — GHRH(1-29), the unmodified active fragment of GHRH. Formerly marketed for diagnostic and pediatric growth hormone deficiency uses and withdrawn from the US market for commercial reasons; now sold for claims it was never tested against. (Ch.15)

Set point — the value toward which a homeostatic system regulates. (Ch.3)

Setmelanotide — an 8-amino-acid cyclic MC4R agonist approved for obesity due to specified rare genetic deficiencies in the leptin–melanocortin pathway; works by acting downstream of the broken step. (Ch.13)

severe drift — See directional bias. Fingerprint: rating ⚠️ or ❌ where the evidence supports ✅,

Severe primary IGF-1 deficiency — A rare condition in which IGF-1 production fails despite normal or

Shared decision-making — an approach in which clinician and patient combine clinical evidence

Side chain — see R group. (Ch.1)

Signal peptide (cosmetic sense) — A peptide proposed to act as a message to fibroblasts prompting

Signal transduction — the conversion of an extracellular signal into an intracellular response. (Ch.2)

Smad2 / Smad3 — Intracellular signal transducers phosphorylated downstream of the myostatin

Small-molecule agonist — a low-molecular-weight non-peptide compound that activates a receptor normally addressed by a peptide, absorbed from the gut as a matter of course and made by conventional organic chemistry. Orforglipron is the GLP-1 receptor example.

Smart insulin — investigational glucose-responsive insulin whose activity would vary with surrounding glucose concentration, restoring the glucose-dependence that insulin lacks. (Ch.11)

SNAC — sodium N-[8-(2-hydroxybenzoyl)amino] caprylate, the absorption enhancer in oral semaglutide; it transiently raises local pH to reduce pepsin activity and promotes absorption across the gastric epithelium. Not a peptide and not the drug.

SNAP-25 — A SNARE protein. Cleaved enzymatically by botulinum toxin type A; the protein from which

snapshot — A reference assembled at one moment, valid as a description of that moment and

SNARE complex — The protein assembly, including SNAP-25, syntaxin, and synaptobrevin, that drives

Social fact — Something that is true because a group treats it as true, independent of any external measurement. "This drug is everywhere" can be a social fact while actual prevalence remains unknown to everyone asserting it. (Ch.41)

Social salience hypothesis — The leading current account of oxytocin's central effects: that it

solid-phase peptide synthesis (SPPS) — Merrifield's 1963 method, in which a peptide chain is

Soluble guanylate cyclase — the cytoplasmic, nitric-oxide-responsive enzyme that produces cGMP. A

Somatopause — The age-related decline in growth hormone secretion and IGF-1, commonly cited as roughly 14% per decade after about age 30. The term's analogy to menopause is rhetorical rather than physiological, since the decline is gradual, partial, and never reaches zero. (Ch.14)

Somatostatin — an inhibitory peptide that brakes growth hormone release and suppresses several pancreatic and gastrointestinal hormones; the basis of an approved oncology drug class. (Ch.3)

Somatostatin analog — An engineered, stabilized relative of somatostatin (octreotide, lanreotide)

Somatostatin receptor (SSTR) — A family of five receptor subtypes; SSTR2 is the principal target

Somatotroph — The cell type in the anterior pituitary that produces and secretes growth hormone. (Ch.14)

Somatotropin — The generic pharmaceutical name for growth hormone; the -tropin stem denotes a pituitary-hormone-like molecule. (Ch.14)

Spacer (linker) — The short chemical bridge between a peptide and an attached lipid or polymer,

Specific force — Force produced per unit of muscle cross-sectional area; a measure of muscle quality

Specification — The written set of tests, methods, and acceptance criteria a batch must meet.

Speculation economy — The set of incentives that makes public guessing about individuals' medical treatment cheap to produce, highly engaging, socially defensible, and never resolved — with the cost falling entirely on the subject. (Ch.41)

split rating — A rating carrying two glyphs separated by a slash (⚠️/❌, ✅/⚠️, ⚠️/🔬) because the

standard of evidence — The threshold required before assigning a given rating. The audit's premise

Stapled peptide — A peptide whose alpha helix is locked in its bound conformation by a hydrocarbon

Statistical significance — the conventional threshold at which a result is unlikely to be chance; it says nothing about whether the effect is large or important. (Ch.5)

Steady state — the stable drug concentration reached after approximately four to five half-lives of regular dosing. (Ch.4)

Stem (drug naming) — the shared suffix or infix in a generic drug name that identifies its class, assigned under international nomenclature conventions: -tide for peptides, -mab for monoclonal antibodies, -relin and -relix for releasing-hormone agonists and antagonists. (Ch.1)

STEP — the clinical development program for semaglutide 2.4 mg in weight management. (Ch.8)

Step therapy — A requirement that a less expensive option be tried and fail before a more expensive one is covered. (Ch.12)

stepwise yield — The fraction of chains that are correct, full-length product after n couplings

Sterility — Absence of viable organisms, achieved by a validated process (terminal sterilization

Stigma — Social devaluation attached to a characteristic or condition. Treated in this book as a

Stimulation test — a diagnostic procedure in which a provoking agent is administered and the

Stopped early for efficacy — termination of a trial when an interim analysis crosses a pre-specified benefit boundary; ethically motivated, and associated with systematically overestimated effect magnitudes. (Ch.10)

Stopping rule — a condition, defined in advance, under which an intervention will be

Stratum corneum — The outermost layer of the epidermis: dead, keratin-filled corneocytes embedded

Strict liability (anti-doping) — The principle that an athlete is responsible for any prohibited

Structural intervention — A change to environments, systems, prices, regulations, or access rather

structurally empty field — A dossier field that is empty because no answer could exist, as

Structure-based design — designing or optimizing a ligand using the three-dimensional structure

Structure/function claim — A claim that a product affects the structure or any function of the

Subcutaneous — injected into the fat layer beneath the skin, from which absorption occurs over hours; the default route for peptide drugs. (Ch.4)

Subscription procurement (delinkage) — A payment model in which a health system pays a fixed sum

Substance P — an 11-residue tachykinin, Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2, released

Superiority trial — a design asking whether a treatment is better than its comparator. (Ch.9)

Suppression — the reduction in endogenous hormone production that follows supplying that hormone from outside; expected physiology rather than a malfunction. (Ch.3)

SURMOUNT — the tirzepatide clinical development program in obesity. (Ch.9)

SURPASS — the tirzepatide clinical development program in type 2 diabetes. (Ch.9)

Surrogate endpoint — a measurement believed to predict a clinically important outcome, used because it is faster or cheaper to measure than the outcome itself. (Ch.5)

Surrogate endpoint (reinforced) — a measurement that stands in for an outcome people care about.

Survivorship bias — the distortion produced when only cases reaching a particular outcome are visible; in testimonial records, the structural reason positive experiences dominate before any reader arrives. (Ch.6)

SUSTAIN — the clinical development program for semaglutide in type 2 diabetes, including SUSTAIN 6, a cardiovascular outcomes trial that found benefit in a study designed to rule out harm. (Ch.8)

Symmetric risk (of pro-healing signals) — The observation that angiogenesis, proliferation, and

Synthetic long peptide [NEW] — a 20–30-residue vaccine peptide that must be processed by

Systematic review — a structured search and critical appraisal of all available evidence on a question. (Ch.5)

Systemic bioavailability — the fraction of an administered dose that reaches systemic circulation

T

T-cell receptor [NEW] — the receptor engaging a peptide-HLA complex; reads the side chains

Tachykinin — the peptide family including substance P, neurokinin A, and neurokinin B, sharing the

Tachyphylaxis — rapid tolerance, developing within hours or over a few doses. (Ch.2)

Tandem mass spectrometry (MS/MS) — isolating an ion, fragmenting it, and measuring the fragment

Tape stripping — Sequential removal of stratum corneum layers with adhesive tape to measure

Target versus drug — the distinction between the molecule a therapy acts on and the molecule the

TB-500 — A laboratory code for a compound marketed as a short synthetic fragment of thymosin β4,

Teichoic acid — Anionic polymers threading the Gram-positive cell wall; a major contributor to

Tendinopathy — the preferred term for chronic tendon disorders, adopted in place of "tendinitis" because these conditions typically show degenerative change, disorganized collagen, and often abnormal neovascularization, with relatively little classic inflammation. (Ch.17)

Teprotide — a bradykinin-potentiating peptide from Bothrops jararaca venom developed as an

Teriparatide — recombinant PTH(1–34), an approved anabolic bone agent for severe osteoporosis and

Terlipressin — a longer-acting vasopressin analog with relative V1 preference, used in esophageal

Terminal sterilization — Sterilization of the product in its final sealed container. — Ch 19

Tertiary structure — the overall three-dimensional arrangement of a folded peptide or protein chain. (Ch.1)

Tesamorelin — A stabilized GHRH analog, and the only compound in Chapter 15 with a regulatory approval: reduction of excess visceral abdominal fat in HIV-associated lipodystrophy. (Ch.15)

Testimonial — a personal account of benefit from a treatment; subject to regression to the mean, natural history, expectation, co-intervention, and survivorship filtering. (Ch.6)

TGF-β superfamily — A large group of secreted signaling proteins sharing receptors and downstream

Theranostic — A targeting system usable for both diagnosis and therapy by exchanging the

Therapeutic relationship — the ongoing clinical relationship itself, whose diagnostic value comes

Therapeutic use exemption — a process by which an athlete may be permitted to use an otherwise prohibited substance for a documented medical need, subject to the relevant organization's requirements (Ch. 38).

Therapeutic vaccine [NEW] — given to treat existing disease, against an immune system that has

Therapeutic window — The range between an effective and a harmful exposure. The general concept

Thymosin alpha-1 (Tα1) — A 28-amino-acid peptide derived from prothymosin alpha, with

Thymosin β4 (Tβ4) — A 43-amino-acid endogenous human peptide, present in essentially all human

Tight junction — The protein complex sealing the space between adjacent epithelial cells; a major

Titration — stepwise increase of a dose over time, usually to allow tolerance to side effects to develop before reaching the target dose. (Ch.4)

Tolerance — the clinical observation that the same dose of a drug produces less effect over time. (Ch.2)

Tonic (continuous) stimulation — Sustained, non-pulsatile receptor stimulation. For some axes it produces a categorically different result from pulsatile stimulation, up to and including suppression. (Ch.15)

Topline results — a sponsor-selected summary of headline numbers released ahead of full data, without the tables that would let a reader check them. Frequently accurate, never sufficient, and not a publication.

Toroidal pore model — A mechanism in which lipid headgroups bend inward with the inserting

Transcellular route — Penetration straight through corneocytes, alternately crossing lipid and

Transection model — an experimental injury created by surgically cutting a structure such as a tendon, ligament, or nerve; acute, complete, standardized, with a known time zero, and therefore structurally unlike most human overuse injuries. (Ch.17)

Transepidermal water loss (TEWL) — The rate at which water passes through skin and evaporates; a

transferable judgment — What survives after the specific content of the book is forgotten: the

Translational gap — the distance between a result in a laboratory model and a result in human patients, crossed only by human trials; the reason roughly nine in ten compounds entering human trials never reach approval. (Ch.17)

Trial registration — the public filing of a clinical trial's design before enrollment begins. Registered, run, completed, results-posted, and peer-reviewed publication are five distinct states, and only the last settles anything. (Ch.17)

Trigeminal ganglion — the sensory ganglion serving the face and meninges. It lies outside the

Tropic hormone — a pituitary hormone whose target is another endocrine gland; ACTH, TSH, LH, FSH, and growth hormone. (Ch.3)

truncated sequence — A chain that stopped growing at some intermediate length. Easier to separate

Tumor mutational burden [NEW] — the number of somatic mutations in a tumor; associated with

Tumor-associated antigen [NEW] — a self protein overexpressed or aberrantly expressed by

Type 1 diabetes — autoimmune destruction of pancreatic beta cells producing absolute insulin deficiency; insulin therapy is required for survival. (Ch.11)

Type 2 diabetes — insulin resistance accompanied by progressive beta cell dysfunction; insulin is one treatment option among several, typically later in the course. (Ch.11)

Type I procollagen — See Procollagen. (Ch 30 §30.3)

U

Undecapeptide — a peptide of eleven amino acid residues. Cyclosporine is a cyclic undecapeptide.

Unfalsifiable claim — A claim compatible with every possible observation, and therefore incapable

Unimolecular dual agonist — a single molecule that activates two different receptors, with an activity ratio fixed by its structure and unchangeable without redesigning the molecule. (Ch.9)

Unnatural amino acid — Any residue outside the standard twenty, used to tune charge,

unpopulated rating — A Field 6 row assigning a symbol without naming the population and endpoint

Uterine atony — Failure of the uterus to contract adequately after delivery, leaving placental-bed

Uterotonic — An agent causing uterine contraction. Oxytocin is a first-line uterotonic worldwide for

V

V1 receptor — the vasopressin receptor subtype on vascular smooth muscle, mediating

V1a receptor — Vasopressin receptor on vascular smooth muscle and in the brain; mediates

V1b receptor — Vasopressin receptor in the anterior pituitary; contributes to ACTH release, linking

V2 receptor — Renal collecting-duct vasopressin receptor; drives aquaporin-2 insertion and water

Vagal afferent — a sensory nerve fiber carrying information from the gut and hepatic portal region to the brain, providing a route by which a peptide's signal reaches the central nervous system without the peptide itself doing so.

Vagus nerve — the major nerve carrying sensory information from the gut to the hindbrain; its afferent endings in the gut wall carry GLP-1 receptors. (Ch.7)

Valid veterinarian-client-patient relationship — The condition that a veterinarian has assumed

Validated instrument — A questionnaire whose measurement properties (internal consistency,

values question — A claim whose load-bearing terms encode a judgment about what ought to be

Values question — A question about what should be done, valued, or prioritized, which evidence can

Vancomycin — a glycopeptide antibiotic, a mainstay against methicillin-resistant *Staphylococcus

Vasodilatory shock — circulatory failure caused by loss of vascular tone, most commonly in the

Vasopressin (arginine vasopressin, AVP) — A nonapeptide hormone; the body's principal

Vasopressor — a drug that raises blood pressure by increasing vascular tone. Vasopressin is a

Vehicle — Everything in a topical product other than the active ingredient. Almost always

Vehicle control — A control arm receiving the identical formulation minus the active ingredient.

Venom peptide — a peptide component of an animal venom: typically short, often stabilized by

verdict-to-question conversion — (reprise) Rewriting a Field 11 verdict as a question a

Vericiguat — a small-molecule stimulator of soluble guanylate cyclase, approved for heart failure

version history — A series of dated snapshots of a dossier. Its value is the trajectory rather

Veterinary pharmacopeia — The body of drugs approved and used in veterinary medicine, including a

Visceral adipose tissue — Fat stored around the abdominal organs, distinct from subcutaneous fat and more strongly associated with metabolic and cardiovascular risk. The endpoint of tesamorelin's approved indication. (Ch.15)

Volume transmission — diffusion of a released signaling molecule beyond its synapse onto cells

Vosoritide — a CNP analog engineered for a usable half-life, approved for achondroplasia on an

W

Wall stress — the mechanical tension in the heart muscle wall, rising with chamber pressure and

Washout period — a mandated interval between stopping one drug and starting another, imposed

well-specified open question — A statement of what is not known, precise enough to name the

Winner's curse (in study reporting) — The systematic inflation of published effect sizes that occurs

Withdrawal period — The interval that must elapse after treating a food-producing animal before

World Anti-Doping Agency (WADA) — the organization that publishes the Prohibited List adopted by anti-doping organizations and sporting federations (Ch. 38).

Wrong-pockets problem — The structural defect by which a payer in a market with membership churn funds prevention whose payoff will accrue to a competitor, and therefore systematically underfunds it. (Ch.12)

Y

Y receptor — the GPCR family (Y1, Y2, Y4, Y5 in humans) through which NPY, peptide YY, and

Z

Ziconotide — a synthetic 25-residue peptide equivalent to a cone snail venom peptide, held by three

Zwitterionic — Carrying both a positive and a negative charge and therefore net neutral.

Α

α-MSH (alpha-melanocyte-stimulating hormone) — the endogenous MC4R agonist; activating the receptor reduces hunger. (Ch.13)

Β

β-endorphin — a 31-residue endogenous opioid peptide derived from proopiomelanocortin, with high

Ω

ω-Conotoxin MVIIA — the conotoxin from Conus magus that blocks N-type voltage-gated calcium